Document and Entity Information
Document and Entity Information - shares | 9 Months Ended | |
Mar. 31, 2022 | May 09, 2022 | |
Document and Entity Information [Abstract] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Document Period End Date | Mar. 31, 2022 | |
Entity File Number | 001-40159 | |
Entity Registrant Name | InnovAge Holding Corp. | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 81-0710819 | |
Entity Address, Address Line One | 8950 E. Lowry Boulevard | |
Entity Address, City or Town | Denver | |
Entity Address State Or Province | CO | |
Entity Address, Postal Zip Code | 80230 | |
City Area Code | 844 | |
Local Phone Number | 803-8745 | |
Title of 12(b) Security | Common Stock, $0.001 par value | |
Trading Symbol | INNV | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | true | |
Entity Ex Transition Period | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 135,525,006 | |
Entity Central Index Key | 0001834376 | |
Current Fiscal Year End Date | --06-30 | |
Document Fiscal Year Focus | 2022 | |
Document Fiscal Period Focus | Q3 | |
Amendment Flag | false |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2022 | Jun. 30, 2021 |
Current Assets | ||
Cash and cash equivalents | $ 199,493 | $ 201,466 |
Restricted cash | 18 | 2,234 |
Accounts receivable, net of allowance ($3,921 - March 31, 2022 and $4,350 - June 30, 2021) | 31,905 | 32,582 |
Prepaid expenses and other | 13,572 | 9,249 |
Income tax receivable | 5,461 | 5,401 |
Total current assets | 250,449 | 250,932 |
Noncurrent Assets | ||
Property and equipment, net | 163,882 | 142,715 |
Investments | 5,493 | 3,493 |
Deposits and other | 5,378 | 3,877 |
Goodwill | 124,217 | 124,217 |
Intangible assets, net | 8,772 | 6,518 |
Total noncurrent assets | 307,742 | 280,820 |
Total assets | 558,191 | 531,752 |
Current Liabilities | ||
Accounts payable and accrued expenses | 41,834 | 32,361 |
Reported and estimated claims | 36,012 | 33,234 |
Due to Medicaid and Medicare | 9,530 | 7,101 |
Current portion of long-term debt | 3,793 | 3,790 |
Current portion of capital lease obligations | 3,216 | 2,079 |
Total current liabilities | 94,385 | 78,565 |
Noncurrent Liabilities | ||
Deferred tax liability, net | 15,781 | 15,700 |
Capital lease obligations | 10,282 | 5,190 |
Other noncurrent liabilities | 2,570 | 2,758 |
Long-term debt, net of debt issuance costs | 69,051 | 71,574 |
Total liabilities | 192,069 | 173,787 |
Commitments and Contingencies (See Note 9) | ||
Redeemable Noncontrolling Interests (See Note 4) | 15,996 | 16,986 |
Stockholders' Equity | ||
Common stock, $0.001 par value; 500,000,000 authorized as of March 31, 2022 and June 30, 2021; 135,525,006 and 135,516,513 shares issued and outstanding as of March 31, 2022 and June 30, 2021, respectively | 136 | 136 |
Additional paid-in capital | 326,346 | 323,760 |
Retained earnings | 17,437 | 10,663 |
Total InnovAge Holding Corp. | 343,919 | 334,559 |
Noncontrolling interests | 6,207 | 6,420 |
Total stockholders' equity | 350,126 | 340,979 |
Total liabilities and stockholders' equity | $ 558,191 | $ 531,752 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands | Mar. 31, 2022 | Jun. 30, 2021 |
Condensed Consolidated Balance Sheets | ||
Allowance for loss | $ 3,921 | $ 4,350 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock authorized (in shares) | 500,000,000 | 500,000,000 |
Common stock issued (in shares) | 135,525,006 | 135,516,513 |
Common stock outstanding (in shares) | 135,525,006 | 135,516,513 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Mar. 31, 2022 | Mar. 31, 2021 | Mar. 31, 2022 | Mar. 31, 2021 | |
Revenues | ||||
Total revenues | $ 177,359 | $ 156,308 | $ 525,780 | $ 466,184 |
Expenses | ||||
External provider costs | 103,254 | 75,389 | 284,299 | 224,215 |
Cost of care, excluding depreciation and amortization | 46,102 | 39,565 | 129,740 | 115,922 |
Sales and marketing | 6,144 | 5,592 | 19,117 | 14,335 |
Corporate, general and administrative | 24,682 | 18,595 | 74,248 | 105,901 |
Depreciation and amortization | 3,850 | 3,311 | 10,435 | 9,262 |
Equity loss | 1,343 | |||
Other operating income | 19,222 | 18,211 | ||
Total expenses | 184,032 | 161,674 | 517,839 | 489,189 |
Operating Income (Loss) | (6,673) | (5,366) | 7,941 | (23,005) |
Other Income (Expense) | ||||
Interest expense, net | (709) | (4,876) | (1,930) | (17,061) |
Loss on extinguishment of debt | (13,488) | (14,479) | ||
Gain on equity method investment | 10,871 | 10,871 | ||
Other income (expense) | 108 | (2,267) | (358) | (2,222) |
Total other expense | (601) | (9,760) | (2,288) | (22,891) |
Income (Loss) Before Income Taxes | (7,274) | (15,126) | 5,653 | (45,896) |
Provision (Benefit) for Income Taxes | (4,116) | (4,264) | 81 | 5,159 |
Net Income (Loss) | (3,158) | (10,862) | 5,572 | (51,055) |
Less: net loss attributable to noncontrolling interests | (337) | (352) | (616) | (595) |
Net Income (Loss) Attributable to InnovAge Holding Corp. | $ (2,821) | $ (10,510) | $ 6,188 | $ (50,460) |
Weighted-average number of common shares outstanding - basic | 135,516,608 | 121,324,980 | 135,516,544 | 119,619,806 |
Weighted-average number of common shares outstanding - diluted | 135,516,608 | 121,324,980 | 135,530,793 | 119,619,806 |
Net income (loss) per share - basic | $ (0.02) | $ (0.09) | $ 0.05 | $ (0.42) |
Net income (loss) per share - diluted | $ (0.02) | $ (0.09) | $ 0.05 | $ (0.42) |
Capitation revenue | ||||
Revenues | ||||
Total revenues | $ 176,988 | $ 155,835 | $ 524,507 | $ 464,294 |
Other service revenue | ||||
Revenues | ||||
Total revenues | $ 371 | $ 473 | $ 1,273 | $ 1,890 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands | Common Stock | Additional Paid-in Capital | Retained Earnings (Deficit) | Treasury Stock | Noncontrolling Interests | Total |
Balances, Beginning at Jun. 30, 2020 | $ 133 | $ 36,338 | $ 64,737 | $ (193) | $ 6,735 | $ 107,750 |
Balances, Beginning (in shares) at Jun. 30, 2020 | 132,718,461 | 102,030 | ||||
Balances, Ending at Dec. 31, 2020 | $ 133 | 24,552 | 15,330 | $ (77,796) | 6,492 | (31,289) |
Balances, Ending (in shares) at Dec. 31, 2020 | 132,718,461 | 16,197,849 | ||||
Balances, Beginning at Jun. 30, 2020 | $ 133 | 36,338 | 64,737 | $ (193) | 6,735 | 107,750 |
Balances, Beginning (in shares) at Jun. 30, 2020 | 132,718,461 | 102,030 | ||||
Treasury stock transaction | $ (77,603) | (77,603) | ||||
Treasury stock transaction (in shares) | 16,095,819 | |||||
Treasury stock retirement | $ (16) | (77,780) | $ 77,796 | |||
Treasury stock retirement (in shares) | (16,197,849) | (16,197,849) | ||||
Stock Option Cancellation, Value | (9,457) | (9,457) | ||||
Time based awards- option cancelation | (32,358) | (32,358) | ||||
Stock-based compensation | 1,102 | 1,102 | ||||
Reclassification of warrant liability | 2,264 | 2,264 | ||||
Owner contribution | 20,000 | 20,000 | ||||
Initial public offering of common stock, net of offering costs | $ 19 | 373,561 | 373,580 | |||
Initial public offering of common stock, net of offering costs (in shares) | 18,995,901 | |||||
Net income (loss) | (50,460) | (332) | (50,792) | |||
Net income (loss) | (51,055) | |||||
Adjustment to redemption value | (344) | (344) | ||||
Balances, Ending at Mar. 31, 2021 | $ 136 | 323,127 | 4,476 | 6,403 | 334,142 | |
Balances, Ending (in shares) at Mar. 31, 2021 | 135,516,513 | |||||
Redeemable non-controlling interests (Temporary Equity) | ||||||
Temporary Equity, Accretion to Redemption Value, Adjustment | 16,838 | |||||
Adjustment to redemption value | 344 | |||||
Net income (loss) | (263) | |||||
Ending balance at Mar. 31, 2021 | 16,919 | |||||
Redeemable non-controlling interests (Temporary Equity) | ||||||
Net Income (Loss) Attributable to Redeemable Noncontrolling Interest | (51,055) | |||||
Balances, Beginning at Dec. 31, 2020 | $ 133 | 24,552 | 15,330 | $ (77,796) | 6,492 | (31,289) |
Balances, Beginning (in shares) at Dec. 31, 2020 | 132,718,461 | 16,197,849 | ||||
Treasury stock retirement | $ (16) | (77,780) | $ 77,796 | |||
Treasury stock retirement (in shares) | (16,197,849) | (16,197,849) | ||||
Stock-based compensation | 530 | 530 | ||||
Reclassification of warrant liability | 2,264 | 2,264 | ||||
Initial public offering of common stock, net of offering costs | $ 19 | 373,561 | 373,580 | |||
Initial public offering of common stock, net of offering costs (in shares) | 18,995,901 | |||||
Net income (loss) | (10,510) | (89) | (10,599) | |||
Net income (loss) | (10,862) | |||||
Adjustment to redemption value | (344) | (344) | ||||
Balances, Ending at Mar. 31, 2021 | $ 136 | 323,127 | 4,476 | 6,403 | 334,142 | |
Balances, Ending (in shares) at Mar. 31, 2021 | 135,516,513 | |||||
Redeemable non-controlling interests (Temporary Equity) | ||||||
Temporary Equity, Accretion to Redemption Value, Adjustment | 16,838 | |||||
Adjustment to redemption value | 344 | |||||
Net income (loss) | (263) | |||||
Ending balance at Mar. 31, 2021 | 16,919 | |||||
Redeemable non-controlling interests (Temporary Equity) | ||||||
Net Income (Loss) Attributable to Redeemable Noncontrolling Interest | (10,862) | |||||
Balances, Beginning at Jun. 30, 2021 | $ 136 | 323,760 | 10,663 | 6,420 | 340,979 | |
Balances, Beginning (in shares) at Jun. 30, 2021 | 135,516,513 | |||||
Stock-based compensation | 2,586 | 2,586 | ||||
Stock-based compensation (in shares) | 8,493 | |||||
Net income (loss) | 6,188 | (213) | 5,975 | |||
Net income (loss) | 5,572 | |||||
Adjustment to redemption value | 586 | 586 | ||||
Balances, Ending at Mar. 31, 2022 | $ 136 | 326,346 | 17,437 | 6,207 | 350,126 | |
Balances, Ending (in shares) at Mar. 31, 2022 | 135,525,006 | |||||
Beginning balance at Jun. 30, 2021 | 16,986 | |||||
Redeemable non-controlling interests (Temporary Equity) | ||||||
Adjustment to redemption value | (586) | |||||
Net income (loss) | (403) | |||||
Ending balance at Mar. 31, 2022 | 15,996 | |||||
Redeemable non-controlling interests (Temporary Equity) | ||||||
Net Income (Loss) Attributable to Redeemable Noncontrolling Interest | 5,572 | |||||
Balances, Beginning at Dec. 31, 2021 | $ 136 | 325,501 | 17,695 | 6,254 | 349,586 | |
Balances, Beginning (in shares) at Dec. 31, 2021 | 135,516,513 | |||||
Stock-based compensation | 845 | 845 | ||||
Stock-based compensation (in shares) | 8,493 | |||||
Net income (loss) | (2,821) | (47) | (2,868) | |||
Net income (loss) | (3,158) | |||||
Adjustment to redemption value | 2,563 | 2,563 | ||||
Balances, Ending at Mar. 31, 2022 | $ 136 | $ 326,346 | $ 17,437 | $ 6,207 | 350,126 | |
Balances, Ending (in shares) at Mar. 31, 2022 | 135,525,006 | |||||
Beginning balance at Dec. 31, 2021 | 18,850 | |||||
Redeemable non-controlling interests (Temporary Equity) | ||||||
Adjustment to redemption value | (2,563) | |||||
Net income (loss) | (290) | |||||
Ending balance at Mar. 31, 2022 | 15,996 | |||||
Redeemable non-controlling interests (Temporary Equity) | ||||||
Net Income (Loss) Attributable to Redeemable Noncontrolling Interest | $ (3,158) |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended |
Mar. 31, 2021 | Mar. 31, 2021 | |
Condensed Consolidated Statements of Stockholders' Equity | ||
Offering costs | $ 25,334 | $ 25,334 |
Condensed Consolidated Statem_4
Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 9 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Operating Activities | ||
Net income (loss) | $ 5,572 | $ (51,055) |
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities | ||
Loss on disposal of assets | 358 | 2 |
Provision for uncollectible accounts | 4,834 | 4,144 |
Depreciation and amortization | 10,435 | 9,262 |
Gain on equity method investment | (10,871) | |
Loss on extinguishment of long-term debt | 8,494 | |
Amortization of deferred financing costs | 322 | 948 |
Stock-based compensation | 2,586 | 1,102 |
Deferred income taxes | 81 | (3,464) |
Change in fair value of warrants | 2,264 | |
Change in fair value of contingent consideration | 1,343 | |
Changes in operating assets and liabilities, net of acquisitions | ||
Accounts receivable, net | (4,157) | (1,402) |
Prepaid expenses and other | (4,323) | 635 |
Income tax receivable | (60) | 1,613 |
Deposits and other | (1,501) | (606) |
Accounts payable and accrued expenses | 4,705 | 7,717 |
Reported and estimated claims | 2,778 | 114 |
Due to Medicaid and Medicare | 2,429 | 12,732 |
Net cash provided by (used in) operating activities | 24,059 | (17,028) |
Investing Activities | ||
Purchases of property and equipment | (20,141) | (14,083) |
Purchase of intangible assets | (1,437) | (2,000) |
Purchase of cost method investment | (2,000) | |
Net cash used in investing activities | (23,578) | (16,083) |
Financing Activities | ||
Distributions to owners | (9,458) | |
Owner contributions | 20,000 | |
Payments on capital lease obligations | (1,829) | (1,685) |
Proceeds from long-term debt | 375,000 | |
Principal payments on long-term debt | (2,841) | (512,649) |
Payment of financing costs and debt premiums | (8,896) | |
Proceeds from initial public offering of common stock | 373,580 | |
Treasury stock purchases | (77,603) | |
Payments under acquisition agreements | (3,622) | |
Payments related to option cancellation | (32,358) | |
Net cash provided by (used in) financing activities | (4,670) | 122,309 |
INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS & RESTRICTED CASH | (4,189) | 89,198 |
CASH, CASH EQUIVALENTS & RESTRICTED CASH, BEGINNING OF PERIOD | 203,700 | 114,565 |
CASH, CASH EQUIVALENTS & RESTRICTED CASH, END OF PERIOD | 199,511 | 203,763 |
Supplemental Cash Flows Information | ||
Interest paid | 1,452 | 16,251 |
Income taxes paid | 84 | 7,047 |
Prepayment penalty on extinguishment of debt | 6,000 | |
Intangibles and property and equipment included in accounts payable | 4,577 | 224 |
Property and equipment purchased under capital leases | $ 8,057 | $ 3,517 |
Business
Business | 9 Months Ended |
Mar. 31, 2022 | |
Business | |
Business | Note 1: Business InnovAge Holding Corp. (formerly, TCO Group Holdings, Inc.) was formed May 13, 2016, to acquire the business of Total Community Options, Inc. d/b/a InnovAge, which was formed in May 2007. In connection with the Company’s initial public offering (“IPO”), which occurred in March 2021, we changed the name of our Company from TCO Group Holdings, Inc. to InnovAge Holding Corp. InnovAge Holding Corp. and its subsidiaries, are headquartered in Denver, Colorado. The Company manages, and in many cases directly provides, a broad range of medical and ancillary services for seniors in need of care and support to safely live independently in their homes and communities, including in-home care services (skilled, unskilled and personal care); in-center services such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to the Program of All-Inclusive Care for the Elderly (“PACE”) center and third-party medical appointments; and care management. The Company manages its business as one reportable segment, PACE. As of March 31, 2022, the Company served approximately 6,800 PACE participants, making it the largest PACE provider in the United States of America (the “U.S.”) based upon participants served, and operates 18 PACE centers across Colorado, California, New Mexico, Pennsylvania and Virginia. PACE is a fully-capitated managed care program, which serves the frail elderly, and predominantly dual-eligible, population in a community-based service model. InnovAge is obligated to provide and participants receive all needed healthcare services through an all-inclusive, coordinated model of care, and the Company is at risk for 100% of healthcare costs incurred with respect to the care of its participants. PACE programs receive capitation payments directly from Medicare Parts C and D, Medicaid, Veterans Administration (“VA”), and private pay sources. Additionally, under the Medicare Prescription Drug Plan, the Centers for Medicare and Medicaid Services (“CMS”) share part of the risk for providing prescription medication to the Company’s participants. On March 8, 2021, we completed our IPO. The Company’s common stock began trading on the Nasdaq Stock Market LLC (“NASDAQ”) under the ticker symbol “INNV”. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 9 Months Ended |
Mar. 31, 2022 | |
Summary of Significant Accounting Policies | |
Summary of Significant Accounting Policies | Note 2: The Company described its significant accounting policies in Note 2, “Summary of Significant Accounting Policies” of the Notes to Consolidated Financial Statements in its Annual Report on Form 10-K for the year ended June 30, 2021 (“2021 10-K”). During the nine months ended March 31, 2022, there were no significant changes to those accounting policies. Basis of Preparation and Principles of Consolidation The unaudited interim condensed consolidated financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the U.S. (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such regulations. These financial statements have been prepared on a basis consistent with the accounting principles applied for the fiscal year ended June 30, 2021. In the opinion of management, all adjustments (consisting of all normal and recurring adjustments) considered necessary for a fair presentation have been included. The condensed consolidated financial statements include the accounts of InnovAge, its wholly owned subsidiaries, variable interest entities (“VIEs”) for which it is the primary beneficiary and entities for which it has a controlling interest. All intercompany accounts and transactions have been eliminated in consolidation. The Company does not have any components of comprehensive income and comprehensive income is equal to net income reported in the statements of operations for all periods presented. Restatement of Prior Period Financial Statements Subsequent to the issuance of the Company’s consolidated financial statements as of and for the year ended June 30, 2021, we identified an error in our consolidated balance sheet and statement of stockholders’ equity as of June 30, 2021 related to the presentation of redeemable noncontrolling interests. Additionally, the error also impacted our condensed consolidated statements of shareholders’ equity for the three months and nine-months ended March 31, 2021. The Company incorrectly recorded redeemable noncontrolling interests of $17.0 million and $16.9 million as permanent equity rather than temporary equity The effect of the restatement on the consolidated balance sheet as of June 30, 2021 is as follows ( in thousands As Previously Reported Adjustments As Restated Redeemable Noncontrolling Interests (See Note 4) — 16,986 16,986 Retained earnings 11,250 (587) 10,663 Total InnovAge Holding Corp. 335,146 (587) 334,559 Noncontrolling interests 22,819 (16,399) 6,420 Total stockholders’ equity 357,965 (16,986) 340,979 The effect of the restatement on the balances as of June 30, 2021 included in the consolidated statement of stockholders’ equity as of March 31, 2022 is as follows ( in thousands Redeemable Total Permanent Noncontrolling Retained Noncontrolling Stockholders’ Interests Earnings Interests Equity (Temporary Equity) As Previously Reported Balances, June 30, 2021 11,250 22,819 357,965 — Adjustments Balances, June 30, 2021 (587) (16,399) (16,986) 16,986 As Restated Balances, June 30, 2021 10,663 6,420 340,979 16,986 The effect of the restatement on the consolidated statement of stockholders’ equity for the three months ended March 31, 2021 is as follows ( in thousands Redeemable Total Permanent Noncontrolling Retained Noncontrolling Stockholders’ Interests Retained Earnings Interests Equity (Temporary Equity) Earnings As Previously Reported Consolidation of equity method investment — 16,838 16,838 — — Net income (loss) (10,510) (352) (10,862) — — Adjustment to redemption value — — — — — Balances, March 31, 2021 4,820 22,978 351,061 — — Adjustments Consolidation of equity method investment — (16,838) (16,838) 16,838 — Net income (loss) — 263 263 (263) (10,862) Adjustment to redemption value (344) — (344) 344 — Balances, March 31, 2021 (344) (16,575) (16,919) 16,919 — As Restated Consolidation of equity method investment — — — 16,838 — Net income (loss) (10,510) (89) (10,599) (263) (10,862) Adjustment to redemption value (344) — (344) 344 — Balances, March 31, 2021 4,476 6,403 334,142 16,919 — The effect of the restatement on the consolidated statement of stockholders’ equity for the nine months ended March 31, 2021 is as follows ( in thousands Redeemable Total Permanent Noncontrolling Retained Noncontrolling Stockholders’ Interests Retained Earnings Interests Equity (Temporary Equity) Earnings As Previously Reported Consolidation of equity method investment — 16,838 16,838 — — Net income (loss) (50,460) (595) (51,055) — — Adjustment to redemption value — — — — — Balances, March 31, 2021 4,820 22,978 351,061 — — Adjustments Consolidation of equity method investment — (16,838) (16,838) 16,838 — Net income (loss) — 263 263 (263) (51,055) Adjustment to redemption value (344) — (344) 344 — Balances, March 31, 2021 (344) (16,575) (16,919) 16,919 — As Restated Consolidation of equity method investment — — — 16,838 — Net income (loss) (50,460) (332) (50,792) (263) (51,055) Adjustment to redemption value (344) — (344) 344 — Balances, March 31, 2021 4,476 6,403 334,142 16,919 — Property and Equipment Property and equipment were comprised of the following as of March 31, 2022 and June 30, 2021: Estimated dollars in thousands Useful Lives March 31, 2022 June 30, 2021 Land N/A $ 11,980 $ 11,980 Buildings and leasehold improvements 10 - 40 years 121,661 104,724 Software 3 - 5 years 15,107 13,316 Equipment and vehicles 3 - 7 years 46,655 35,341 Construction in progress N/A 22,336 22,130 217,739 187,491 Less accumulated depreciation and amortization (53,857) (44,776) Total property and equipment, net $ 163,882 $ 142,715 Depreciation of $3.8 million and $3.2 million was recorded during the three months ended March 31, 2022 and 2021, respectively. Depreciation of $9.9 million and $8.8 million was recorded during the nine months ended March 31, 2022 and 2021, respectively. Coronavirus Pandemic (“COVID-19”) As a PACE organization, we have been and will continue to be impacted by the effects of COVID-19. We closed all our centers in March 2020 and transitioned to a 100% in-home and virtual care model. We believe that the general lack of in-person interaction and the reduction in healthcare personnel, and specifically, trained personnel, impacted our ability to adhere to the complex government laws and regulations that apply to our business. We remain committed to carrying out our mission of caring for our participants. We continue to closely monitor the impact of COVID-19 on all aspects of our business, including the impacts to our employees, participants and suppliers. Due to the numerous evolving factors, we are unable to reliably estimate the ultimate impact the pandemic will have on our consolidated financial condition, results of operations or cash flows. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was signed into legislation. Under the CARES Act, the state of Pennsylvania signed into law the Act 24 of 2020. We received $1.0 million in funding under the Act 24 of 2020, which was allocated to InnovAge centers in Pennsylvania. Of the $1.0 million, $0.7 million was recognized prior June 30, 2020 and the remaining balance of $0.3 million was recognized during the year ended June 30, 2021. The CARES Act also provides for the temporary suspension of the automatic 2% reduction of Medicare claim reimbursements (sequestration) for the period of May 1, 2020 through December 31, 2020. The Consolidated Appropriations Act, 2021, enacted December 27, 2020, extended this suspension for three more months, through March 31, 2021. H.R. 1868, enacted on April 14, 2021 further extends the suspension through December 31, 2021. On December 10, 2021 the “Protecting Medicare and American Farmers from Sequester Cuts Act” extends the 2% Medicare sequester moratorium through March 31, 2022, and adjusts the sequester to 1% between April 1, 2022 and June 30, 2022. Recently Adopted Accounting Pronouncements Income Taxes In December 2019, the Financial Accounting Standards Board (“FASB”) issued ASU 2019-12, Income Taxes Topic 740-Simplifying the Accounting for Income Taxes Recent Accounting Pronouncements Not Yet Adopted Leases In February 2016, the FASB issued ASU 2016-02 Leases Revenue from contracts with customers (Topic 606) and leases (Topic 842)—Effective dates for certain entities Financial Instruments In April 2019, the FASB issued ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments—Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments ( ) We do not expect that any other recently issued accounting guidance will have a significant effect on our condensed consolidated financial statements. |
Revenue Recognition
Revenue Recognition | 9 Months Ended |
Mar. 31, 2022 | |
Revenue Recognition | |
Revenue Recognition | Note 3: Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performed the following five steps: (i) Identify the contract(s) with a customer; (ii) Identify the performance obligations in the contract; (iii) Determine the transaction price; (iv) Allocate the transaction price to the performance obligations in the contract; and (v) Recognize revenue as the entity satisfies a performance obligation. Capitation Revenue and Accounts Receivable Our capitation revenue relates to contracts with participants in which our performance obligation is to provide healthcare services to the participants. Revenues are recorded during the period our obligations to provide healthcare services are satisfied as noted below within each service type. The Company contracts directly with Medicare and Medicaid on a per member, per month (“PMPM”) basis. We receive 100% of the pooled capitated payment to directly provide or manage the healthcare needs of our participants. Fees are recorded gross in revenues because the Company is acting as a principal in providing for or overseeing comprehensive care provided to the participants. Neither the Company nor any of its affiliates is a registered insurance company because state law in the states in which it operates does not require such registration for risk-bearing providers. In general, a participant enrolls in the PACE program and is considered a customer of InnovAge. The Company considers all contracts with participants as a single performance obligation to provide comprehensive medical, health, and social services that integrate acute and long-term care. The Company identified that contracts with customers in the PACE program have similar performance obligations and therefore groups them into one portfolio. This performance obligation is satisfied as the Company provides comprehensive care to its participants. Our revenues are based on the estimated PMPM amounts we expect to be entitled to receive from the capitated fees per participant that are paid monthly by Medicaid, Medicare, the VA, and private pay sources. Medicaid and Medicare capitation revenues are based on PMPM capitation rates under the PACE program. VA is included in “Private Pay and other” and is also capitated. Private pay includes direct payments from participants who do not qualify for the full capitated rate and have to pay all or a portion of the capitated rate. The Company disaggregates capitation revenue from the following sources for the nine months ended: March 31, 2022 2021 Medicaid 53 % 53 % Medicare 46 % 46 % Private pay and other 1 % 1 % Total 100 % 100 % The Company determined the transaction price for these contracts is the amount we expect to be entitled to, which is the most likely amount. For certain capitation payments, the Company is subject to retroactive premium risk adjustments based on various factors. The Company estimates the amount of the adjustment and records it monthly on a straight-line basis. These adjustments are not expected to be material. The capitation revenues are recognized based on the estimated PMPM transaction price to transfer the service for a distinct increment of the series (i.e. month). We recognize revenue in the month in which participants are entitled to receive comprehensive care benefits during the contract term. As the period between the time of service and time of payment is typically one year or less, the Company elected the practical expedient under ASC 606-10-32-18 and did not adjust for the effects of a significant financing component. The Company also provides prescription drug benefits in accordance with Medicare Part D. Monthly payments received from CMS and the participants represent the bid amount for providing prescription drug coverage. The portion received from CMS is subject to risk sharing through Medicare Part D risk-sharing corridor provisions. These risk-sharing corridor provisions compare costs targeted in the Company’s bid to actual prescription drug costs. The Company estimates and records a monthly adjustment to Medicare Part D revenues associated with these risk-sharing corridor provisions. Medicare Part D comprised (i) 12% of capitation revenues for both the nine months ended March 31, 2022 and 2021 and (ii) 23% and 25% of external provider costs for the nine months ended March 31, 2022 and 2021, respectively. Our accounts receivable as of March 31, 2022 and June 30, 2021 is primarily from capitation revenue arrangements. The concentration of net receivables from participants and third-party payers was as follows: March 31, June 30, 2022 2021 Medicaid 50 % 60 % Medicare 37 % 20 % Private pay and other 13 % 20 % Total 100 % 100 % The Company records accounts receivable at net realizable value, which includes an allowance for estimated uncollectible accounts. The allowance for uncollectible accounts reflects the Company’s best estimate of probable losses considering eligibility, historical experience, and existing economic conditions. The balance of the allowance for uncollectible accounts was $3.9 million as of March 31, 2022, compared to $4.4 million as of June 30, 2021. Accounts are written off as bad debts when they are deemed uncollectible based upon individual credit evaluations and specific circumstances underlying the accounts. Other Service Revenue and Accounts Receivable Other service revenue is comprised of rents earned related to Senior Housing and other fee for service revenue. Other service revenue was 0.2% and 0.4% of total revenue for the nine months ended March 31, 2022 and 2021, respectively, and 0.2% and 0.3% for the three months ended March 31, 2022 and 2021, respectively. Accounts receivable related to other service revenue were not significant as of both March 31, 2022 and June 30, 2021. Laws and regulations governing the Medicare and Medicaid programs are complex and subject to change, as well as government review. Failure to comply with these laws can expose the entity to significant regulatory action, including fines, penalties, and exclusion from the Medicare and Medicaid programs. See Note 9, “Commitments and Contingencies”. |
Investments
Investments | 9 Months Ended |
Mar. 31, 2022 | |
Investments | |
Investments | Note 4: The Company holds equity method and cost method investments as of: March 31, June 30, in thousands 2022 2021 Cost method investments $ 4,645 $ 2,645 Equity method investments 848 848 Total investments $ 5,493 $ 3,493 Nonconsolidated Entities Cost Method Investments The Company maintains two investments that are accounted for using the cost method. The investments do not have a readily determinable fair value and the Company has elected to record the investments at cost, less impairment, if any, plus or minus any changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. During the nine months ended March 31, 2022 and 2021, there were no observable price changes or impairments recorded. Jetdoc In August 2021, the Company acquired a minority interest equal to 806,481 shares of the outstanding common stock of Jetdoc, Inc. (“Jetdoc”), a telehealth and virtual urgent care app dedicated to effectively connecting users with medical professionals, for cash consideration of $2.0 million. The balance of the Company’s investment in Jetdoc is $2.0 million which represents the maximum exposure to loss. Dispatch Health Since 2019, the Company has maintained an investment of $2.6 million in DispatchHealth Holdings, Inc. (“Dispatch Health”). Dispatch Health offers complete in-home on-demand healthcare. The balance of the Company’s investment is $2.6 million which represents the maximum exposure to loss. Equity Method Investments Pinewood Lodge The Company’s operations include a Senior Housing unit that primarily includes the accounts of Continental Community Housing (“CCH”), the general partner of Pinewood Lodge, LLP (“ PWD”) which was organized to develop, construct, own, maintain, and operate certain apartment complexes intended for rental to low-income elderly individuals aged 62 or older. PWD is a VIE, but the Company is not the primary beneficiary. The Company does not have the power to direct the activities that most significantly impact the economic performance of PWD. Accordingly, the Company does not consolidate PWD. PWD is accounted for using the equity method of accounting. The equity earnings of PWD are insignificant. As of March 31, 2022, the balance of the Company’s investment in PWD is $0.8 million which represents the maximum exposure to loss. Noncontrolling Interest Senior Housing The Company’s operations include a 0.01% partnership interest in InnovAge Senior Housing Thornton, LLC (“SH1”), which was organized to develop, construct, own, maintain, and operate certain apartment complexes intended for rental to low-income elderly individuals aged 62 or older. SH1 is a VIE. The Company is the primary beneficiary of SH1 and consolidates SH1. The Company is the primary beneficiary of SH1 as it has the power to direct the activities that are most significant to SH1 and has an obligation to absorb losses or the right to receive benefits from SH1. The most significant activity of SH1 is the operation of the senior housing facility. The Company has provided a subordinated loan to SH1 and has provided a guarantee for a convertible term loan held by SH1. Redeemable Noncontrolling Interest InnovAge Sacramento On March 18, 2019, in connection with the formation of InnovAge Sacramento, the joint venture with Adventist Health System/West (“Adventist”) and Eskaton Properties, Incorporated (“Eskaton”), the Company contributed $9.0 million in cash and land valued at $4.2 million for a 59.9% membership interest in the joint venture, InnovAge Sacramento. Further, Adventist contributed $5.8 million in cash and Eskaton contributed $3.0 million in cash for membership interests of 26.4% and 13.7%, respectively. Prior to January 1, 2021, the Company did not consolidate InnovAge Sacramento. In the third quarter of fiscal year 2021, the Company made an additional contribution of $52,000 to obtain an additional 0.1% membership interest in the joint venture. With the acquisition of the additional 0.1% membership interest, the Company obtained control of InnovAge Sacramento effective January 1, 2021. Accordingly, beginning January 1, 2021, the results of InnovAge Sacramento are included in our consolidated results of operations. Before consolidation on January 1, 2021, the Company recorded its proportionate share of net loss, which was a loss of $1.3 million for the six months ended December 31, 2020, as equity loss in the statement of operations. When the joint venture was formed, the Company issued warrants to Adventist (the “Sacramento Warrants”) to purchase 5% of its issued and outstanding common stock par value $0.001 per share, at an exercise price equal to the fair market value per share at the time of exercise of the warrant. Pursuant to the original warrants, the Sacramento Warrants were to fully vest on the date on which Adventist would have made aggregate capital contributions in an amount greater than $25.0 million to one or more joint venture entities in which Adventist and the Company held equity (the “Investment Threshold”). On February 9, 2021, we entered into an amendment agreement with Adventist to amend the Sacramento Warrants. The amendment removes the Investment Threshold requirement and grants Adventist the right to purchase up to $15.0 million of our common stock at an exercise price equal to the initial public offering price. The warrant was exercisable for one At inception, the Sacramento Warrants were initially determined to be equity-based payments to nonemployees and as such the measurement date for these warrants was considered to be the date when the Investment Threshold is reached. At the time of the amendment, due to the removal of the Investment Threshold, the Sacramento Warrants were evaluated under ASC 815-40, “ Contracts in an Entity’s Own Equity As described above, we obtained control of InnovAge Sacramento through acquisition of an additional 0.1% membership interest, which we consider to be a step acquisition, whereby the Company remeasured the previously held equity method investment to fair value. The amount by which the purchase price exceeds the fair value of the net assets acquired is recorded as goodwill. The fair value of the previously held equity investments was determined using a discounted cash flow model. This resulted in recording a gain on consolidation of $10.9 million during the third quarter of fiscal year 2021. The InnovAge California PACE-Sacramento LLC Limited Liability Company Agreement (the “JV Agreement”) includes numerous provisions whereby, if certain conditions are met, the Joint Venture may be required to purchase, at fair market value, certain members’ interests or certain members may be required to purchase, at fair market value, the interests of certain other members. As of March 31, 2022, none of the conditions specified in the JV Agreement had been met. At the time the Company became a publicly traded company these put rights held by the noncontrolling interests of the Joint Venture were required to be presented as temporary equity. The redeemable noncontrolling interest of $15.9 million was recorded at carrying value as of March 31, 2022. |
Fair Value Measurements
Fair Value Measurements | 9 Months Ended |
Mar. 31, 2022 | |
Fair Value Measurements | |
Fair Value Measurements | Note 5: Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants, at the measurement date. A fair value hierarchy was established that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs are inputs that reflect the assumptions market participants would use in pricing the asset or liability developed based on market data obtained from sources outside the reporting entity. Unobservable inputs are inputs that reflect the Company’s own assumptions based on market data and assumptions that market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The sensitivity to changes in inputs and their impact on fair value measurements can be significant. The three levels of inputs that may be used to measure fair value are: Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability to access at the measurement date Level 2 Quoted prices in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the assets or liabilities Level 3 Unobservable inputs to the valuation techniques that are significant to the fair value measurements of the assets or liabilities Recurring Measurements The Company’s investment in InnovAge Sacramento includes a put right for the noncontrolling interest holders to require the Company to repurchase the interest of the noncontrolling interest holders at fair value, after the initial term of the management services agreement in 2028. As a result, at each fiscal period end the Company reports this put right at the greater of i) carrying value of the redeemable noncontrolling interest or (ii) fair value of the redeemable noncontrolling interest. Because this asset does not have observable inputs, level 3 inputs are used to measure fair value. For the three months ended March 31, 2022, the Company recorded an adjustment to redemption value of the redeemable noncontrolling interest of $2.6 million, which was a reduction to carrying value. This adjustment represents the excess amount of fair value over the carrying value as of March 31, 2022. The fair value of the redeemable noncontrolling interest is determined utilizing a discounted cash flow model. Effective August 7, 2018, the Company finalized the acquisition of NewCourtland LIFE Program (“NewCourtland”) in Pennsylvania. The Company paid a base purchase price of $30.0 million, subject to certain net working capital and closing adjustments plus contingent consideration of up to $20.0 million. On March 8, 2021, we completed our IPO, which satisfied the condition that the Company sell equity securities pursuant to an effective registration statement. Accordingly, $20.0 million of contingent consideration was paid under the terms of the acquisition agreement. Since all of the contingent consideration of $20.0 million was paid, the lease payments in certain real estate leases between the Company and NewCourtland were reduced from their current amounts and allow the Company to exercise its option to purchase the leased buildings at fair market value, after the initial term of the lease. As of June 30, 2021 and March 31, 2022, there are no amounts of contingent consideration outstanding. There were no transfers in and out of Level 3 during the nine months ended March 31, 2022 or 2021. |
Goodwill and Intangible Assets
Goodwill and Intangible Assets | 9 Months Ended |
Mar. 31, 2022 | |
Goodwill and Intangible Assets | |
Goodwill and Intangible Assets | Note 6: Goodwill, which represents the excess of consideration paid over the fair value of net assets acquired through business acquisitions. Goodwill amounted to $124.2 million at each of March 31, 2022 and June 30, 2021. Goodwill is not amortized. Pursuant to ASC 350, “ Intangibles – Goodwill and Other Intangibles assets consisted of the following as of: March 31, June 30, in thousands 2022 2021 Definite-lived intangible assets $ 9,350 $ 6,600 Indefinite-lived intangible assets 2,000 2,000 Total intangible assets 11,350 8,600 Accumulated amortization (2,578) (2,082) Balance as of end of period $ 8,772 $ 6,518 Intangible assets consist primarily of customer relationships acquired through business acquisitions and technology-based assets. The Company recorded amortization expense of $0.5 million and $0.2 million for the nine months ended March 31, 2022 and 2021, respectively. We review the recoverability of other intangible assets in conjunction with long-lived assets whenever events or changes in circumstances indicate the carrying amount of such assets may not be recoverable. There were no intangible asset impairments recorded during the nine months ended March 31, 2022 and 2021. During the nine months ended March 31, 2022, the market value of our common stock declined below the carrying value of equity. As a result, we were required to qualitatively assess whether a triggering event had occurred and whether it was more likely than not that our goodwill was impaired as of March 31, 2022. We believe the impact of the regulatory actions described below to our planned opening of new centers and expansion into new service areas met the criteria of a triggering event, which required us to perform quantitative procedures as part of a Step 1 goodwill impairment analysis to asses whether it was more-likely-than-not that the fair value of the Company was greater than the net book value. In September 2021, we were notified that CMS and the State of California had determined to suspend new enrollments at our Sacramento center based on deficiencies detected in an audit related to participant provision of services. In December 2021, we were notified that CMS and Colorado Department of Health Care Policy and Financing (“HCPF”) had determined to suspend new enrollments at our Colorado centers based on deficiencies detected in an audit related to participant provision of services. In each case, the suspensions will remain in effect until CMS and the respective States determine that we have remediated the deficiencies to their satisfaction. During the third quarter ended March 31, 2022, we were notified by the State of Kentucky that they no longer intend to enter into an agreement with us relating to PACE services, and during the same period, CMS denied our initial application to develop a PACE center in the State of Indiana. As a result of the above assessment, we concluded that there was no goodwill impairment based on a review of macroeconomic and industry considerations, the Company's financial results in each of our reporting units for the nine months ended March 31, 2022 and financial projections, inclusive of a sustained impact of the enrollment suspension and inability to open new centers. If assumptions or estimates in the fair value calculations change or if future cash flows vary from what was expected, including those assumptions relating to the duration and severity of the financial impact of the enrollment suspension at Sacramento and Colorado or new regulatory sanctions or other actions are imposed on the Company, this may impact the impairment analysis and could reduce the underlying cash flows used to estimate fair values and result in a decline in fair value that may trigger future impairment charges. |
Leases
Leases | 9 Months Ended |
Mar. 31, 2022 | |
Leases | |
Leases | Note 7: Property and equipment includes property under various capital leases. These leases have expiration dates ranging from August 2022 to July 2032, varying interest rates, and generally include an option to purchase the equipment at the end of the underlying lease period. The Company’s capital leases included the following at March 31, 2022 and June 30, 2021: March 31, 2022 June 30, 2021 in thousands Equipment $ 18,885 $ 13,302 Less accumulated depreciation (7,150) (7,081) Total capital leases $ 11,735 $ 6,221 Certain of the Company’s property and equipment is leased under operating leases. Such leases generally have lease terms ranging from years 2022 through 2032 with renewal options. Total rental expense under operating leases was $1.3 million and $3.5 million for the three and nine months ended March 31, 2022, respectively, and $1.4 million and $3.5 million for the three and nine months ended March 31, 2021 respectively. Future minimum lease payments for fiscal years beginning with remainder of fiscal year 2022 for capital leases having initial terms of more than one year and noncancelable operating leases were as follows: Operating Leases Capital Leases Minimum Lease in thousands Obligations Payments Amount remaining in 2022 $ 958 $ 1,203 2023 4,405 4,872 2024 3,909 4,582 2025 3,126 4,122 2026 2,092 4,061 Thereafter 1,927 14,029 Total 16,417 $ 32,869 Less amount representing interest (2,912) Total minimum lease payments 13,498 Less current maturities (3,216) Noncurrent maturities $ 10,282 |
Long Term Debt
Long Term Debt | 9 Months Ended |
Mar. 31, 2022 | |
Long Term Debt | |
Long Term Debt | Note 8. Long Term Debt Long-term debt consisted of the following at March 31, 2022 and June 30, 2021: Interest rate Maturity date March 31, 2022 June 30, 2021 in thousands Senior secured borrowings: Term Loan Facility (a) March 8, 2026 $ 72,188 $ 75,000 Revolving Credit Facility (b) (a) March 8, 2026 — — Convertible term loan 6.68% August 20, 2030 2,338 2,367 Total debt 74,526 77,367 Less unamortized debt issuance costs 1,681 2,003 Less current maturities 3,793 3,790 Noncurrent maturities $ 69,051 $ 71,574 (a) The interest rates on the Term Loan Facility and Revolving Credit Facility are described below. (b) The remaining capacity under the Revolving Credit Facility as of March 31, 2022 was $100.0 million, subject to (i) any issued amounts under our letters of credit, which as of March 31, 2022 was $2.6 million, and (ii) applicable covenant compliance restrictions and any other conditions precedent to borrowing. 2016 Credit Agreement The Company originally entered into a senior secured borrowing agreement (the “2016 Credit Agreement”) on May 13, 2016, that consisted of a senior secured term loan for $75.0 million and a revolving credit facility for $20.0 million. The 2016 Credit Agreement was subsequently amended (i) on May 2, 2019 to increase the senior secured term loan to $190.0 million and a revolving credit facility for $30.0 million and a delayed draw term loan facility (“DDTL”) for $45.0 million and (ii) on July 27, 2020, to increase the senior secured term loan to $300.0 million, the revolving credit facility to $40.0 million and to terminate Concurrent with the Company’s entry into the 2021 Credit Agreement (as defined below), the Company terminated and repaid in full all outstanding indebtedness under the 2016 Credit Agreement. 2021 Credit Agreement On March 8, 2021, concurrently with the closing of the IPO, the Company entered into a new credit agreement (the “2021 Credit Agreement”) that replaced the 2016 Credit Agreement. The 2021 Credit Agreement consists of a senior secured term loan (the “Term Loan Facility”) of $75.0 million principal amount and a revolving credit facility (the “Revolving Credit Facility”) of $100.0 million maximum borrowing capacity. Loans under the 2021 Credit Agreement are secured by substantially all of the Company’s assets. Principal on the Term Loan Facility is paid each calendar quarter beginning September 2021 in an amount equal to 1.25% of the initial term loan on closing date. Proceeds of the Term Loan Facility, together with proceeds from the IPO, were used to repay amounts outstanding under the 2016 Credit Agreement. Outstanding principal amounts under the 2021 Credit Agreement accrue interest at a variable interest rate. As of March 31, 2022, the interest rate on the Term Loan Facility was 2.21%. Under the terms of the 2021 Credit Agreement, the Revolving Credit Facility fee accrues at 0.25% of the average daily unused amount and is paid quarterly. As of March 31, 2022, we had no borrowings outstanding under the Revolving Credit Facility. The 2021 Credit Agreement requires the Company to meet certain operational and reporting requirements, including, but not limited to, a secured net leverage ratio. Additionally, annual capital expenditures and permitted investments, including acquisitions, are limited to amounts specified in the 2021 Credit Agreement. The 2021 Credit Agreement also provides certain restrictions on dividend payments and other equity transactions and requires the Company to make prepayments under specified circumstances. As of March 31, 2022, the Company was in compliance with the covenants of the 2021 Credit Agreement. The deferred financing costs of $2.0 million are amortized over the term of the underlying debt and unamortized amounts have been offset against long-term debt in the consolidated balance sheets. Total amortization of deferred financing costs was $0.3 million for the nine months ended March 31, 2022. Convertible Term Loan On June 29, 2015, SH1 entered into a convertible term loan. Monthly principal and interest payments of $0.02 million commenced on September 1, 2015. The loan is secured by a deed of trust to Public Trustee, assignment of leases and rents, security agreements, and SH1’s fixture filing. |
Commitments and Contingencies
Commitments and Contingencies | 9 Months Ended |
Mar. 31, 2022 | |
Commitments and Contingencies | |
Commitments and Contingencies | Note 9: Commitments and Contingencies Professional Liability The Company pays fixed premiums for annual professional liability insurance coverage under a claims-made policy. Under such policy, only claims made and reported to the insurer are covered during the policy term, regardless of when the incident giving rise to the claim occurred. The Company records claim liabilities and expected recoveries, if any, at gross amounts. The Company is not currently aware of any unasserted claims or unreported incidents that are expected to exceed medical malpractice insurance coverage limits. Litigation From time to time, in the normal course of business, the Company is involved in or subject to legal proceedings related to its business, including those described below. The Company regularly evaluates the status of claims and legal proceedings in which it is involved in order to assess whether a loss is probable or there is a reasonable possibility that a loss may have been incurred, and to determine if accruals are appropriate. The Company expenses legal costs as such costs are incurred. On October 14, 2021, the Company was named as a defendant in a putative class action complaint filed in the District Court for the District of Colorado on behalf of individuals who purchased or acquired shares of the Company’s common stock during a specified period. Through the complaint, plaintiffs are asserting claims against the Company, certain of the Company’s officers and the underwriters in the Company’s IPO, alleging violations of Sections 11 and 15 of the Securities Act of 1933 for making allegedly inaccurate and misleading statements and omissions in connection with the Company’s IPO and seeking compensatory damages, among other things. The plaintiffs have indicated that they intend to file an amended complaint on or before June 14, 2022. We are currently unable to predict the outcome of this matter. In July 2021, the Company received a civil investigative demand from the Attorney General for the State of Colorado under the Colorado Medicaid False Claims Act. The demand requests information and documents regarding Medicaid billing, patient services and referrals in connection with the Company’s PACE program in Colorado. We continue to fully cooperate with the Attorney General and produce the requested information and documentation. We are currently unable to predict the outcome of this investigation. In February 2022, the Company received a civil investigative demand from the Department of Justice (“DOJ”) under the Federal False Claims Act on similar subject matter. The demand requests information and documents regarding audits, billing, orders tracking, and quality and timeliness of patient services in connection with the Company’s PACE programs in the states where the Company operates (California, Colorado, New Mexico, Pennsylvania, and Virginia). The Company is fully cooperating with the DOJ to produce the requested information and documentation. We are currently unable to predict the outcome of this investigation. On April 20, 2022, the Board of Directors of the Company received a books and records demand pursuant to Section 220 of the Delaware General Corporation Law, from a purported stockholder of the Company, in connection with the stockholder’s investigation of, among other matters, potential breaches of fiduciary duty, mismanagement, self-dealing, corporate waste or other violations of law by the Company’s Board with respect to these matters. We are currently unable to predict the outcome of this matter. Although the results of legal proceedings and claims are inherently unpredictable and uncertain, we do not believe that the outcomes of the legal proceedings with which we are currently involved, based on the currently available information, either individually or in the aggregate, will have a material adverse effect on our business, financial condition, or cash flows, though the outcomes could be material to the Company’s operating results for any particular period; depending in part, upon the operating results of such period. Regardless of the outcome, litigation has the potential to have an adverse impact on us due to any related defense and settlement costs, diversion of management resources, and other factors. |
Equity
Equity | 9 Months Ended |
Mar. 31, 2022 | |
Equity | |
Equity | Note 10: Equity Owner Transaction On July 27, 2020, InnovAge Holding Corp. (formerly TCO Group Holdings, Inc.), Ignite Aggregator LP (“Purchaser”), and the former equity holders of InnovAge Holding Corp. (“Sellers”) entered into a Securities Purchase Agreement (the “Agreement”), effective July 27, 2020. Under the terms of the Agreement, the Sellers sold a portion of their equity interest to the Purchaser. The Purchaser and the Sellers then contributed their equity interests in the Company to a newly formed limited partnership, TCO Group Holdings, L.P. (the “LP”) resulting in the Company being wholly owned by the LP. Concurrently with the entry into the Agreement, the Company amended and restated its 2016 Credit Agreement, see Note 8, “Long Term Debt” for further discussion. A portion of the proceeds from the 2016 Credit Agreement were used by the Company to repurchase 16,095,819 shares of its common stock for $77.6 million from certain members of management, including certain members of the Board of Directors, and certain members of our equity partner. The common stock was then recognized as Treasury stock. The Treasury stock was retired in March 2021. Additionally, as part of the Agreement, the Company executed an Option Cancellation Agreement (the “Cancellation Agreement”), which canceled the Company’s common stock option awards of 16,994,975 granted under the 2016 Equity Incentive Plan for $74.6 million. Such cancellation resulted in a settlement of the awards. Vesting of the contingent performance-based awards was not deemed probable at the time of the settlement resulting in the settlement of the contingent performance-based awards being recorded as Corporate, general and administrative. Vesting of the time vesting awards was deemed probable at the time of the settlement resulting in a portion of the settlement of the time vesting awards being recorded as Corporate, general and administrative expense and the remainder being recorded as a reduction to Additional paid-in capital. Of the total settlement, $45.4 million was recorded as Corporate, general and administrative expense and $32.4 million was recorded as a reduction to Additional paid-in capital. The Cancellation Agreement resulted in the option holders receiving the same amount of cash that they would have received had they exercised their options, participated in the repurchase described above and sold their remaining shares. As part of the transaction, for the nine months ended March 31, 2021, the Company incurred $22.6 million in transaction costs, of which $13.1 million was recognized as Corporate, general and administrative expense and $9.5 million was recognized as a distribution to owners as the costs were paid on behalf of the owners. These costs were recorded during the nine months ended March 31, 2021. |
Stock-based Compensation
Stock-based Compensation | 9 Months Ended |
Mar. 31, 2022 | |
Stock-based Compensation | |
Stock-based Compensation | Note 11: A summary of our aggregate stock-based compensation expense is set forth below. Stock-based compensation expense is included in corporate, general and administrative expenses on our consolidated statements of operations. Nine Months Ended March 31, in thousands 2022 2021 Stock options (a) $ 359 $ 45,387 Profits interests units 1,095 1,102 Restricted stock units 1,132 — Total stock-based compensation expense $ 2,586 $ 46,489 (a) The amount for 2021 relates to stock-based compensation expense recognized as a result of the Cancellation Agreement. 2016 Equity Incentive Plan The Company maintained the 2016 Equity Incentive Plan pursuant to which various stock-based awards were granted to employees, directors, consultants, and advisers. The total number of shares of the Company’s common stock that was authorized under the 2016 Equity Incentive Plan was 17,836,636, of which a total of 16,994,976 awards were granted. On July 27, 2020, the Company, Ignite Aggregator LP, and the equity holders of the Company entered into a Securities Purchase Agreement, and in conjunction therewith, the Company amended and restated the 2016 Credit Agreement. A portion of the proceeds from the 2016 Credit Agreement were used by the Company to repurchase 16,095,819 shares of its common stock from the certain members of management, the Board of Directors, and members of our equity partner. Additionally, as part of the 2016 Credit Agreement, the Company executed the Cancellation Agreement with each of the 2016 Equity Incentive Plan option holders, participated in the repurchase described above and sold their remaining shares. The 2016 Equity Incentive Plan was cancelled and replaced with the 2020 Equity Incentive Plan, as described below. 2020 Equity Incentive Plan Profits Interests The LP maintains the 2020 Equity Incentive Plan pursuant to which interests in the LP in the form of Class B Units (profits interests) may be granted to employees, directors, consultants, and advisers. A maximum number of 16,162,177 Class B Units are authorized for grant under the 2020 Equity Incentive Plan. As of March 31, 2022, a total of 13,009,137 profits interests units have been granted under the 2020 Equity Incentive Plan. The Company used the Monte Carlo option model to determine the fair value of the profits interests units at the time of the grant. There were no grants during the nine months ended March 31, 2022. A summary of profits interests activity for the nine months ended March 31, 2022 was as follows: Number of Weighted average Time-based unit awards units grant date fair value Outstanding balance, June 30, 2021 6,587,261 $ 1.28 Forfeited (2,409,972) $ 1.28 Outstanding balance, March 31, 2022 4,177,289 $ 1.28 Number of Weighted average Performance-based unit awards units grant date fair value Outstanding balance, June 30, 2021 6,223,262 $ 0.57 Forfeited (3,210,939) $ 0.57 Outstanding balance, March 31, 2022 3,012,323 $ 0.57 The total unrecognized compensation cost related to profits interests units outstanding as of March 31, 2022 was $6.4 million, comprised (i) $4.3 million related to time-based unit awards expected to be recognized over a weighted-average period of 0.9 years and (ii) $2.1 million related to performance-based unit awards, which will be recorded when it is probable that the performance-based criteria will be met. 2021 Omnibus Incentive Plan In March 2021, the compensation committee of our Board of Directors approved the InnovAge Holding Corp. 2021 Omnibus Incentive Plan (the “2021 Omnibus Incentive Plan”), pursuant to which various stock-based awards may be granted to employees, directors, consultants, and advisers. The total number of shares of the Company’s common stock authorized under the 2021 Omnibus Incentive Plan is 14,700,000. The Company has issued time-based restricted stock units under this plan to its employees which generally vest (i) on March 4, 2023, the second anniversary of the grant date, or (ii) over a three-year period with one Restricted Stock Units A summary of time-based vesting restricted stock units activity for the nine months ended March 31, 2022 was as follows: Weighted average Number of grant-date fair Restricted stock units - time based awards value per share Outstanding balance, June 30, 2021 48,470 $ 22.87 Granted 315,177 $ 8.99 Forfeited (9,670) $ 23.35 Exercised (8,493) $ 17.66 Outstanding balance, March 31, 2022 345,484 $ 10.50 The total unrecognized compensation cost related to time based restricted stock units outstanding as of March 31, 2022 was $4.0 million and is expected to be recognized over a weighted-average period of 2.0 years. A summary of performance based vesting restricted stock units activity for the nine months ended March 31, 2022 was as follows: Weighted average Number of grant-date fair Restricted stock units - performance based awards value per share Outstanding balance, June 30, 2021 — $ — Granted 258,767 $ 5.18 Forfeited — $ — Outstanding balance, March 31, 2022 258,767 $ 5.18 The fair value of the performance based restricted stock units and performance based stock options granted during the nine months ended March 31, 2022, was based upon a Monte Carlo option pricing model using the assumptions in the following table: 2022 Expected volatility 34.5 % Expected term (in years) 5.0 Interest rate 1.56 % Dividend yield 0 % Weighted-average fair values $ 5.18 Fair value of underlying stock $ 7.89 The total unrecognized compensation cost related to performance based vesting restricted stock units outstanding as of March 31, 2022 was $1.2 million and is expected to be recognized over a weighted-average period of 3.6 years. Nonqualified Stock Options A summary of time-based vesting stock option activity for the nine months ended March 31, 2022 was as follows: Weighted average Number of grant-date fair Stock options - time based awards value per share Outstanding balance, June 30, 2021 — $ — Granted 554,499 $ 1.61 Forfeited — $ — Outstanding balance, March 31, 2022 554,499 $ 1.61 The total unrecognized compensation cost related to time-based vesting stock options outstanding as of March 31, 2022 was $0.7 million and is expected to be recognized over a weighted-average period of 2.5 years. The fair value of the time-based stock options granted during the nine months ended March 31, 2022, was based upon the Black-Scholes option pricing model using the assumptions in the following table: 2022 Expected volatility 34.5 % Weighted-average expected life (years) - time vesting units 2.9 Interest rate 0.83 % Dividend yield 0 % Weighted-average fair values $ 1.61 Fair value of underlying stock $ 7.89 A summary of performance-based vesting stock option activity for the nine months ended March 31, 2022 was as follows: Weighted average Number of grant-date fair Stock options - performance based awards value per share Outstanding balance, June 30, 2021 — $ — Granted 776,299 $ 3.08 Forfeited — $ — Outstanding balance, March 31, 2022 776,299 $ 3.08 The fair value of the performance-based stock options granted during the nine months ended March 31, 2022, was based upon a Monte Carlo option pricing model using the assumptions in the table above under the ‘Restricted Stock Units’ heading. The total unrecognized compensation cost related to performance-based vesting stock options outstanding as of March 31, 2022 was $2.2 million and is expected to be recognized over a weighted-average period of 3.6 years. |
Income Taxes
Income Taxes | 9 Months Ended |
Mar. 31, 2022 | |
Income Taxes | |
Income Taxes | Note 12: Income Taxes The Company recorded an income tax benefit of $4.1 million and $4.3 million for the three months ended March 31, 2022 and 2021, respectively. The Company recorded a tax provision of $0.1 million and $5.2 million for the nine months ended March 31, 2022 and 2021, respectively. This represents an effective tax rate of 56.6% and 28.2% for the three months ended March 31, 2022 and 2021, respectively. This represents an effective tax rate of 1.4% and (11.2)% for the nine months ended March 31, 2022 and 2021, respectively. The effective rate for the nine months ended March 31, 2022 was different from the federal statutory rate primarily due to the Company’s book loss offset partially by disallowed officers’ compensation under Internal Revenue Code (“IRC”) Section 162(m) and lobbying expenses which occurred during the nine month period. The Company assesses the valuation allowance recorded against deferred tax assets at each reporting date. The determination of whether a valuation allowance for deferred tax assets is appropriate requires the evaluation of positive and negative evidence that can be objectively verified. Consideration must be given to all sources of taxable income available to realize deferred tax assets, including, as applicable, the future reversal of existing temporary differences, future taxable income forecasts exclusive of the reversal of temporary differences and carryforwards, taxable income in carryback years and tax planning strategies. In estimating income taxes, the Company assesses the relative merits and risks of the appropriate income tax treatment of transactions taking into account statutory, judicial, and regulatory guidance. As of the nine-month period ended March 31, 2022, the Company has determined that it is not “more likely than not” that the deferred tax assets associated with certain state net operating losses will be realized and as such continues to maintain a valuation allowance against these state deferred tax assets. The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of the employer portion of social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitation and technical corrections to tax depreciation methods for qualified improvement property. The Company continues to examine the impacts that the CARES Act may have on its business. While several of these provisions may impact the Company, there have not been any significant impacts noted through March 31, 2022. |
Earnings per Share
Earnings per Share | 9 Months Ended |
Mar. 31, 2022 | |
Earnings per Share | |
Earnings per Share | Note 13: Basic earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed using the weighted-average number of common shares outstanding during the period, plus the dilutive effect of outstanding options, using the treasury stock method and the average market price of the Company’s common stock during the applicable period. When a loss from continuing operations exists, all dilutive securities and potentially dilutive securities are anti-dilutive and are therefore excluded from the computation of diluted earnings per share. When net income from continuing operations exists, performance-based units, are omitted from the calculation of diluted EPS until it is determined that the performance criteria has been met at the end of the reporting period. The following table sets forth the computation of basic and diluted net loss per common share: Three months ended March 31, Nine months ended March 31, in thousands, except share values 2022 2021 2022 2021 Net income (loss) attributable to InnovAge Holding Corp. $ (2,821) $ (10,510) $ 6,188 $ (50,460) Weighted average common shares outstanding (basic) 135,516,608 121,324,980 135,516,544 119,619,806 Earnings (loss) per share - basic $ (0.02) $ (0.09) $ 0.05 $ (0.42) Dilutive shares — — 14,249 — Weighted average common shares outstanding (diluted) 135,516,608 121,324,980 135,530,793 119,619,806 Earnings (loss) per share -diluted $ (0.02) $ (0.09) $ 0.05 $ (0.42) |
Segment Reporting
Segment Reporting | 9 Months Ended |
Mar. 31, 2022 | |
Segment Reporting | |
Segment Reporting | Note 14: The Company applies ASC Topic 280, " Segment Reporting As of March 31, 2022, the Company served approximately 6,800 PACE participants, making it the largest PACE provider in the U.S. based upon participants served, and operates 18 PACE centers across Colorado, California, New Mexico, Pennsylvania and Virginia. PACE, an alternative to nursing homes, is a managed care, capitated program, which serves the frail elderly in a community-based service model. Participants receive all medical services through a comprehensive, consolidated model of care. Capitation payments are received from Medicare parts C and D; Medicaid; the VA, and private pay sources. The Company is at risk for all health and allied care costs incurred with respect to the care of its participants, although it does negotiate discounted rates with its provider network consisting of hospitals, nursing homes, assisted living facilities, and medical specialists. Additionally, under the Medicare Prescription Drug Plan, CMS shares part of the risk for providing prescription medication to the Company’s participants. The Company evaluates performance and allocates capital resources to each segment based on an operating model that is designed to maximize the provision of services provided and profitability. The Company does not review assets by segment and therefore assets by segment are not disclosed below. For the periods presented, all of the Company’s long-lived assets were located in the U.S. and all revenue was earned in the U.S. The Company’s management uses Center-level Contribution Margin as the measure for assessing performance of its segments. Center-level Contribution Margin is defined as total revenues less external provider costs and cost of care (excluding depreciation and amortization), which includes all medical and pharmacy costs. The Company allocates corporate level expenses to its segments with a majority of the allocation going to the PACE segment. The following table summarizes the operating results regularly provided to the CODM by reportable segment for the three months ended March 31, 2022 and 2021: March 31, 2022 March 31, 2021 in thousands PACE All other (1) Totals PACE All other (1) Totals Capitation revenue $ 176,988 $ — $ 176,988 $ 155,835 $ — $ 155,835 Other service revenue 166 205 371 (47) 520 473 Total revenues 177,154 205 177,359 155,788 520 156,308 External provider costs 103,254 — 103,254 75,389 — 75,389 Cost of care, excluding depreciation and amortization 45,995 107 46,102 38,867 698 39,565 Center-level Contribution Margin 27,905 98 28,003 41,532 (178) 41,354 Overhead costs (2) 30,911 (85) 30,826 24,217 (30) 24,187 Depreciation and amortization 3,760 90 3,850 3,181 130 3,311 Equity loss — — — — — — Other operating income — — — 19,222 — 19,222 Interest expense, net (663) (46) (709) (4,824) (52) (4,876) Loss on extinguishment of debt — — — (13,488) — (13,488) Gain on equity method investment — — — 10,871 — 10,871 Other expense (income) 108 — 108 (2,267) — (2,267) Income (Loss) Before Income Taxes $ (7,321) $ 47 $ (7,274) $ (14,796) $ (330) $ (15,126) The following table summarizes the operating results regularly provided to the CODM by reportable segment for the nine months ended March 31, 2022 and 2021: March 31, 2022 March 31, 2021 in thousands PACE All other (1) Totals PACE All other (1) Totals Capitation revenue $ 524,507 $ — $ 524,507 $ 464,294 $ — $ 464,294 Other service revenue 234 1,039 1,273 213 1,677 1,890 Total revenues 524,741 1,039 525,780 464,507 1,677 466,184 External provider costs 284,299 — 284,299 224,215 — 224,215 Cost of care, excluding depreciation and amortization 128,573 1,167 129,740 113,611 2,311 115,922 Center-Level Contribution Margin 111,869 (128) 111,741 126,681 (634) 126,047 Overhead costs (2) 93,463 (98) 93,365 120,249 (13) 120,236 Depreciation and amortization 10,130 305 10,435 8,901 361 9,262 Equity loss — — — 1,343 — 1,343 Other operating (income) expense — — — 18,211 — 18,211 Interest expense, net (1,783) (147) (1,930) (16,919) (142) (17,061) Loss on extinguishment of debt — — — (14,479) — (14,479) Gain on equity method investment — — — 10,871 — 10,871 Other income (357) (1) (358) (2,222) — (2,222) Income (Loss) Before Income Taxes $ 6,136 $ (483) $ 5,653 $ (44,772) $ (1,124) $ (45,896) (1) Center-level Contribution Margin from segments below the quantitative thresholds are attributable to two operating segments of the Company. Those segments consist of Homecare and Senior Housing. Neither of those segments has ever met any of the quantitative thresholds for determining reportable segments. (2) Overhead consists of the Sales and marketing and Corporate, general and administrative financial statement line items. |
Related-party
Related-party | 9 Months Ended |
Mar. 31, 2022 | |
Related-party | |
Related-party | Note 15: Pursuant to the PWD Amended and Restated Agreement of Limited Partnership, the general partner, who is a subsidiary of the Company (the “General Partner”), helped fund operating deficits and shortfalls of PWD in the form of a loan. At each of March 31, 2022 and June 30, 2021, $0.7 million was recorded in Deposits and other. Additionally, the General Partner is paid an administration fee of $35,000 per year. |
Subsequent Events
Subsequent Events | 9 Months Ended |
Mar. 31, 2022 | |
Subsequent Events | |
Subsequent Events | Note 16: Subsequent Events The Company has evaluated subsequent events through May 10, 2022, the date on which the condensed consolidated financial statements were issued. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 9 Months Ended |
Mar. 31, 2022 | |
Summary of Significant Accounting Policies | |
Basis of Preparation and Principles of Consolidation | Basis of Preparation and Principles of Consolidation The unaudited interim condensed consolidated financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the U.S. (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such regulations. These financial statements have been prepared on a basis consistent with the accounting principles applied for the fiscal year ended June 30, 2021. In the opinion of management, all adjustments (consisting of all normal and recurring adjustments) considered necessary for a fair presentation have been included. The condensed consolidated financial statements include the accounts of InnovAge, its wholly owned subsidiaries, variable interest entities (“VIEs”) for which it is the primary beneficiary and entities for which it has a controlling interest. All intercompany accounts and transactions have been eliminated in consolidation. The Company does not have any components of comprehensive income and comprehensive income is equal to net income reported in the statements of operations for all periods presented. |
Restatement of Prior Period Financial Statements | Restatement of Prior Period Financial Statements Subsequent to the issuance of the Company’s consolidated financial statements as of and for the year ended June 30, 2021, we identified an error in our consolidated balance sheet and statement of stockholders’ equity as of June 30, 2021 related to the presentation of redeemable noncontrolling interests. Additionally, the error also impacted our condensed consolidated statements of shareholders’ equity for the three months and nine-months ended March 31, 2021. The Company incorrectly recorded redeemable noncontrolling interests of $17.0 million and $16.9 million as permanent equity rather than temporary equity The effect of the restatement on the consolidated balance sheet as of June 30, 2021 is as follows ( in thousands As Previously Reported Adjustments As Restated Redeemable Noncontrolling Interests (See Note 4) — 16,986 16,986 Retained earnings 11,250 (587) 10,663 Total InnovAge Holding Corp. 335,146 (587) 334,559 Noncontrolling interests 22,819 (16,399) 6,420 Total stockholders’ equity 357,965 (16,986) 340,979 The effect of the restatement on the balances as of June 30, 2021 included in the consolidated statement of stockholders’ equity as of March 31, 2022 is as follows ( in thousands Redeemable Total Permanent Noncontrolling Retained Noncontrolling Stockholders’ Interests Earnings Interests Equity (Temporary Equity) As Previously Reported Balances, June 30, 2021 11,250 22,819 357,965 — Adjustments Balances, June 30, 2021 (587) (16,399) (16,986) 16,986 As Restated Balances, June 30, 2021 10,663 6,420 340,979 16,986 The effect of the restatement on the consolidated statement of stockholders’ equity for the three months ended March 31, 2021 is as follows ( in thousands Redeemable Total Permanent Noncontrolling Retained Noncontrolling Stockholders’ Interests Retained Earnings Interests Equity (Temporary Equity) Earnings As Previously Reported Consolidation of equity method investment — 16,838 16,838 — — Net income (loss) (10,510) (352) (10,862) — — Adjustment to redemption value — — — — — Balances, March 31, 2021 4,820 22,978 351,061 — — Adjustments Consolidation of equity method investment — (16,838) (16,838) 16,838 — Net income (loss) — 263 263 (263) (10,862) Adjustment to redemption value (344) — (344) 344 — Balances, March 31, 2021 (344) (16,575) (16,919) 16,919 — As Restated Consolidation of equity method investment — — — 16,838 — Net income (loss) (10,510) (89) (10,599) (263) (10,862) Adjustment to redemption value (344) — (344) 344 — Balances, March 31, 2021 4,476 6,403 334,142 16,919 — The effect of the restatement on the consolidated statement of stockholders’ equity for the nine months ended March 31, 2021 is as follows ( in thousands Redeemable Total Permanent Noncontrolling Retained Noncontrolling Stockholders’ Interests Retained Earnings Interests Equity (Temporary Equity) Earnings As Previously Reported Consolidation of equity method investment — 16,838 16,838 — — Net income (loss) (50,460) (595) (51,055) — — Adjustment to redemption value — — — — — Balances, March 31, 2021 4,820 22,978 351,061 — — Adjustments Consolidation of equity method investment — (16,838) (16,838) 16,838 — Net income (loss) — 263 263 (263) (51,055) Adjustment to redemption value (344) — (344) 344 — Balances, March 31, 2021 (344) (16,575) (16,919) 16,919 — As Restated Consolidation of equity method investment — — — 16,838 — Net income (loss) (50,460) (332) (50,792) (263) (51,055) Adjustment to redemption value (344) — (344) 344 — Balances, March 31, 2021 4,476 6,403 334,142 16,919 — |
Property and Equipment | Property and Equipment Property and equipment were comprised of the following as of March 31, 2022 and June 30, 2021: Estimated dollars in thousands Useful Lives March 31, 2022 June 30, 2021 Land N/A $ 11,980 $ 11,980 Buildings and leasehold improvements 10 - 40 years 121,661 104,724 Software 3 - 5 years 15,107 13,316 Equipment and vehicles 3 - 7 years 46,655 35,341 Construction in progress N/A 22,336 22,130 217,739 187,491 Less accumulated depreciation and amortization (53,857) (44,776) Total property and equipment, net $ 163,882 $ 142,715 Depreciation of $3.8 million and $3.2 million was recorded during the three months ended March 31, 2022 and 2021, respectively. Depreciation of $9.9 million and $8.8 million was recorded during the nine months ended March 31, 2022 and 2021, respectively. |
Coronavirus Pandemic ("COVID 19") | Coronavirus Pandemic (“COVID-19”) As a PACE organization, we have been and will continue to be impacted by the effects of COVID-19. We closed all our centers in March 2020 and transitioned to a 100% in-home and virtual care model. We believe that the general lack of in-person interaction and the reduction in healthcare personnel, and specifically, trained personnel, impacted our ability to adhere to the complex government laws and regulations that apply to our business. We remain committed to carrying out our mission of caring for our participants. We continue to closely monitor the impact of COVID-19 on all aspects of our business, including the impacts to our employees, participants and suppliers. Due to the numerous evolving factors, we are unable to reliably estimate the ultimate impact the pandemic will have on our consolidated financial condition, results of operations or cash flows. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was signed into legislation. Under the CARES Act, the state of Pennsylvania signed into law the Act 24 of 2020. We received $1.0 million in funding under the Act 24 of 2020, which was allocated to InnovAge centers in Pennsylvania. Of the $1.0 million, $0.7 million was recognized prior June 30, 2020 and the remaining balance of $0.3 million was recognized during the year ended June 30, 2021. The CARES Act also provides for the temporary suspension of the automatic 2% reduction of Medicare claim reimbursements (sequestration) for the period of May 1, 2020 through December 31, 2020. The Consolidated Appropriations Act, 2021, enacted December 27, 2020, extended this suspension for three more months, through March 31, 2021. H.R. 1868, enacted on April 14, 2021 further extends the suspension through December 31, 2021. On December 10, 2021 the “Protecting Medicare and American Farmers from Sequester Cuts Act” extends the 2% Medicare sequester moratorium through March 31, 2022, and adjusts the sequester to 1% between April 1, 2022 and June 30, 2022. |
Recently Adopted Accounting Pronouncements | Recently Adopted Accounting Pronouncements Income Taxes In December 2019, the Financial Accounting Standards Board (“FASB”) issued ASU 2019-12, Income Taxes Topic 740-Simplifying the Accounting for Income Taxes |
Recent Accounting Pronouncements Not Yet Adopted | Recent Accounting Pronouncements Not Yet Adopted Leases In February 2016, the FASB issued ASU 2016-02 Leases Revenue from contracts with customers (Topic 606) and leases (Topic 842)—Effective dates for certain entities Financial Instruments In April 2019, the FASB issued ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments—Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments ( ) We do not expect that any other recently issued accounting guidance will have a significant effect on our condensed consolidated financial statements. |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Tables) | 9 Months Ended |
Mar. 31, 2022 | |
Summary of Significant Accounting Policies | |
Schedule of effect of restatement on financial statements | As Previously Reported Adjustments As Restated Redeemable Noncontrolling Interests (See Note 4) — 16,986 16,986 Retained earnings 11,250 (587) 10,663 Total InnovAge Holding Corp. 335,146 (587) 334,559 Noncontrolling interests 22,819 (16,399) 6,420 Total stockholders’ equity 357,965 (16,986) 340,979 The effect of the restatement on the balances as of June 30, 2021 included in the consolidated statement of stockholders’ equity as of March 31, 2022 is as follows ( in thousands Redeemable Total Permanent Noncontrolling Retained Noncontrolling Stockholders’ Interests Earnings Interests Equity (Temporary Equity) As Previously Reported Balances, June 30, 2021 11,250 22,819 357,965 — Adjustments Balances, June 30, 2021 (587) (16,399) (16,986) 16,986 As Restated Balances, June 30, 2021 10,663 6,420 340,979 16,986 The effect of the restatement on the consolidated statement of stockholders’ equity for the three months ended March 31, 2021 is as follows ( in thousands Redeemable Total Permanent Noncontrolling Retained Noncontrolling Stockholders’ Interests Retained Earnings Interests Equity (Temporary Equity) Earnings As Previously Reported Consolidation of equity method investment — 16,838 16,838 — — Net income (loss) (10,510) (352) (10,862) — — Adjustment to redemption value — — — — — Balances, March 31, 2021 4,820 22,978 351,061 — — Adjustments Consolidation of equity method investment — (16,838) (16,838) 16,838 — Net income (loss) — 263 263 (263) (10,862) Adjustment to redemption value (344) — (344) 344 — Balances, March 31, 2021 (344) (16,575) (16,919) 16,919 — As Restated Consolidation of equity method investment — — — 16,838 — Net income (loss) (10,510) (89) (10,599) (263) (10,862) Adjustment to redemption value (344) — (344) 344 — Balances, March 31, 2021 4,476 6,403 334,142 16,919 — The effect of the restatement on the consolidated statement of stockholders’ equity for the nine months ended March 31, 2021 is as follows ( in thousands Redeemable Total Permanent Noncontrolling Retained Noncontrolling Stockholders’ Interests Retained Earnings Interests Equity (Temporary Equity) Earnings As Previously Reported Consolidation of equity method investment — 16,838 16,838 — — Net income (loss) (50,460) (595) (51,055) — — Adjustment to redemption value — — — — — Balances, March 31, 2021 4,820 22,978 351,061 — — Adjustments Consolidation of equity method investment — (16,838) (16,838) 16,838 — Net income (loss) — 263 263 (263) (51,055) Adjustment to redemption value (344) — (344) 344 — Balances, March 31, 2021 (344) (16,575) (16,919) 16,919 — As Restated Consolidation of equity method investment — — — 16,838 — Net income (loss) (50,460) (332) (50,792) (263) (51,055) Adjustment to redemption value (344) — (344) 344 — Balances, March 31, 2021 4,476 6,403 334,142 16,919 — |
Schedule of property and equipment | Estimated dollars in thousands Useful Lives March 31, 2022 June 30, 2021 Land N/A $ 11,980 $ 11,980 Buildings and leasehold improvements 10 - 40 years 121,661 104,724 Software 3 - 5 years 15,107 13,316 Equipment and vehicles 3 - 7 years 46,655 35,341 Construction in progress N/A 22,336 22,130 217,739 187,491 Less accumulated depreciation and amortization (53,857) (44,776) Total property and equipment, net $ 163,882 $ 142,715 |
Revenue Recognition (Tables)
Revenue Recognition (Tables) | 9 Months Ended |
Mar. 31, 2022 | |
Revenue Recognition | |
Schedule of source of revenue | March 31, 2022 2021 Medicaid 53 % 53 % Medicare 46 % 46 % Private pay and other 1 % 1 % Total 100 % 100 % |
Schedule of concentration of net receivable | March 31, June 30, 2022 2021 Medicaid 50 % 60 % Medicare 37 % 20 % Private pay and other 13 % 20 % Total 100 % 100 % |
Investments (Tables)
Investments (Tables) | 9 Months Ended |
Mar. 31, 2022 | |
Investments | |
Schedule of equity method and cost method investments | March 31, June 30, in thousands 2022 2021 Cost method investments $ 4,645 $ 2,645 Equity method investments 848 848 Total investments $ 5,493 $ 3,493 |
Goodwill and Intangible Assets
Goodwill and Intangible Assets (Tables) | 9 Months Ended |
Mar. 31, 2022 | |
Goodwill and Intangible Assets | |
Summary of intangible assets by major class | March 31, June 30, in thousands 2022 2021 Definite-lived intangible assets $ 9,350 $ 6,600 Indefinite-lived intangible assets 2,000 2,000 Total intangible assets 11,350 8,600 Accumulated amortization (2,578) (2,082) Balance as of end of period $ 8,772 $ 6,518 |
Leases (Tables)
Leases (Tables) | 9 Months Ended |
Mar. 31, 2022 | |
Leases | |
Schedule of Company's capital leases | March 31, 2022 June 30, 2021 in thousands Equipment $ 18,885 $ 13,302 Less accumulated depreciation (7,150) (7,081) Total capital leases $ 11,735 $ 6,221 |
Schedule of capital lease obligations | Future minimum lease payments for fiscal years beginning with remainder of fiscal year 2022 for capital leases having initial terms of more than one year and noncancelable operating leases were as follows: Operating Leases Capital Leases Minimum Lease in thousands Obligations Payments Amount remaining in 2022 $ 958 $ 1,203 2023 4,405 4,872 2024 3,909 4,582 2025 3,126 4,122 2026 2,092 4,061 Thereafter 1,927 14,029 Total 16,417 $ 32,869 Less amount representing interest (2,912) Total minimum lease payments 13,498 Less current maturities (3,216) Noncurrent maturities $ 10,282 |
Schedule of operating lease minimum lease payments | Operating Leases Capital Leases Minimum Lease in thousands Obligations Payments Amount remaining in 2022 $ 958 $ 1,203 2023 4,405 4,872 2024 3,909 4,582 2025 3,126 4,122 2026 2,092 4,061 Thereafter 1,927 14,029 Total 16,417 $ 32,869 Less amount representing interest (2,912) Total minimum lease payments 13,498 Less current maturities (3,216) Noncurrent maturities $ 10,282 |
Long Term Debt (Tables)
Long Term Debt (Tables) | 9 Months Ended |
Mar. 31, 2022 | |
Long Term Debt | |
Schedule of long-term debt | Interest rate Maturity date March 31, 2022 June 30, 2021 in thousands Senior secured borrowings: Term Loan Facility (a) March 8, 2026 $ 72,188 $ 75,000 Revolving Credit Facility (b) (a) March 8, 2026 — — Convertible term loan 6.68% August 20, 2030 2,338 2,367 Total debt 74,526 77,367 Less unamortized debt issuance costs 1,681 2,003 Less current maturities 3,793 3,790 Noncurrent maturities $ 69,051 $ 71,574 (a) The interest rates on the Term Loan Facility and Revolving Credit Facility are described below. (b) The remaining capacity under the Revolving Credit Facility as of March 31, 2022 was $100.0 million, subject to (i) any issued amounts under our letters of credit, which as of March 31, 2022 was $2.6 million, and (ii) applicable covenant compliance restrictions and any other conditions precedent to borrowing. |
Stock-based Compensation (Table
Stock-based Compensation (Tables) | 9 Months Ended |
Mar. 31, 2022 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Schedule of stock-based compensation expense | Nine Months Ended March 31, in thousands 2022 2021 Stock options (a) $ 359 $ 45,387 Profits interests units 1,095 1,102 Restricted stock units 1,132 — Total stock-based compensation expense $ 2,586 $ 46,489 (a) The amount for 2021 relates to stock-based compensation expense recognized as a result of the Cancellation Agreement. |
Summary of profits interests transactions and number of units outstanding | Number of Weighted average Time-based unit awards units grant date fair value Outstanding balance, June 30, 2021 6,587,261 $ 1.28 Forfeited (2,409,972) $ 1.28 Outstanding balance, March 31, 2022 4,177,289 $ 1.28 Number of Weighted average Performance-based unit awards units grant date fair value Outstanding balance, June 30, 2021 6,223,262 $ 0.57 Forfeited (3,210,939) $ 0.57 Outstanding balance, March 31, 2022 3,012,323 $ 0.57 |
Time-based option awards | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Summary of weighted-average assumptions | 2022 Expected volatility 34.5 % Weighted-average expected life (years) - time vesting units 2.9 Interest rate 0.83 % Dividend yield 0 % Weighted-average fair values $ 1.61 Fair value of underlying stock $ 7.89 |
Summary of stock option activity | Weighted average Number of grant-date fair Stock options - time based awards value per share Outstanding balance, June 30, 2021 — $ — Granted 554,499 $ 1.61 Forfeited — $ — Outstanding balance, March 31, 2022 554,499 $ 1.61 |
Summary of restricted stock units activity | Weighted average Number of grant-date fair Restricted stock units - time based awards value per share Outstanding balance, June 30, 2021 48,470 $ 22.87 Granted 315,177 $ 8.99 Forfeited (9,670) $ 23.35 Exercised (8,493) $ 17.66 Outstanding balance, March 31, 2022 345,484 $ 10.50 |
Performance-based option awards | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Summary of weighted-average assumptions | 2022 Expected volatility 34.5 % Expected term (in years) 5.0 Interest rate 1.56 % Dividend yield 0 % Weighted-average fair values $ 5.18 Fair value of underlying stock $ 7.89 |
Summary of stock option activity | Weighted average Number of grant-date fair Stock options - performance based awards value per share Outstanding balance, June 30, 2021 — $ — Granted 776,299 $ 3.08 Forfeited — $ — Outstanding balance, March 31, 2022 776,299 $ 3.08 |
Summary of restricted stock units activity | Weighted average Number of grant-date fair Restricted stock units - performance based awards value per share Outstanding balance, June 30, 2021 — $ — Granted 258,767 $ 5.18 Forfeited — $ — Outstanding balance, March 31, 2022 258,767 $ 5.18 |
Earnings per Share (Tables)
Earnings per Share (Tables) | 9 Months Ended |
Mar. 31, 2022 | |
Earnings per Share | |
Schedule of earnings per share | The following table sets forth the computation of basic and diluted net loss per common share: Three months ended March 31, Nine months ended March 31, in thousands, except share values 2022 2021 2022 2021 Net income (loss) attributable to InnovAge Holding Corp. $ (2,821) $ (10,510) $ 6,188 $ (50,460) Weighted average common shares outstanding (basic) 135,516,608 121,324,980 135,516,544 119,619,806 Earnings (loss) per share - basic $ (0.02) $ (0.09) $ 0.05 $ (0.42) Dilutive shares — — 14,249 — Weighted average common shares outstanding (diluted) 135,516,608 121,324,980 135,530,793 119,619,806 Earnings (loss) per share -diluted $ (0.02) $ (0.09) $ 0.05 $ (0.42) |
Segment Reporting (Tables)
Segment Reporting (Tables) | 9 Months Ended |
Mar. 31, 2022 | |
Segment Reporting | |
Schedule of operating results by reportable segments | March 31, 2022 March 31, 2021 in thousands PACE All other (1) Totals PACE All other (1) Totals Capitation revenue $ 176,988 $ — $ 176,988 $ 155,835 $ — $ 155,835 Other service revenue 166 205 371 (47) 520 473 Total revenues 177,154 205 177,359 155,788 520 156,308 External provider costs 103,254 — 103,254 75,389 — 75,389 Cost of care, excluding depreciation and amortization 45,995 107 46,102 38,867 698 39,565 Center-level Contribution Margin 27,905 98 28,003 41,532 (178) 41,354 Overhead costs (2) 30,911 (85) 30,826 24,217 (30) 24,187 Depreciation and amortization 3,760 90 3,850 3,181 130 3,311 Equity loss — — — — — — Other operating income — — — 19,222 — 19,222 Interest expense, net (663) (46) (709) (4,824) (52) (4,876) Loss on extinguishment of debt — — — (13,488) — (13,488) Gain on equity method investment — — — 10,871 — 10,871 Other expense (income) 108 — 108 (2,267) — (2,267) Income (Loss) Before Income Taxes $ (7,321) $ 47 $ (7,274) $ (14,796) $ (330) $ (15,126) The following table summarizes the operating results regularly provided to the CODM by reportable segment for the nine months ended March 31, 2022 and 2021: March 31, 2022 March 31, 2021 in thousands PACE All other (1) Totals PACE All other (1) Totals Capitation revenue $ 524,507 $ — $ 524,507 $ 464,294 $ — $ 464,294 Other service revenue 234 1,039 1,273 213 1,677 1,890 Total revenues 524,741 1,039 525,780 464,507 1,677 466,184 External provider costs 284,299 — 284,299 224,215 — 224,215 Cost of care, excluding depreciation and amortization 128,573 1,167 129,740 113,611 2,311 115,922 Center-Level Contribution Margin 111,869 (128) 111,741 126,681 (634) 126,047 Overhead costs (2) 93,463 (98) 93,365 120,249 (13) 120,236 Depreciation and amortization 10,130 305 10,435 8,901 361 9,262 Equity loss — — — 1,343 — 1,343 Other operating (income) expense — — — 18,211 — 18,211 Interest expense, net (1,783) (147) (1,930) (16,919) (142) (17,061) Loss on extinguishment of debt — — — (14,479) — (14,479) Gain on equity method investment — — — 10,871 — 10,871 Other income (357) (1) (358) (2,222) — (2,222) Income (Loss) Before Income Taxes $ 6,136 $ (483) $ 5,653 $ (44,772) $ (1,124) $ (45,896) (1) Center-level Contribution Margin from segments below the quantitative thresholds are attributable to two operating segments of the Company. Those segments consist of Homecare and Senior Housing. Neither of those segments has ever met any of the quantitative thresholds for determining reportable segments. (2) Overhead consists of the Sales and marketing and Corporate, general and administrative financial statement line items. |
Business (Details)
Business (Details) | 9 Months Ended | |
Mar. 31, 2022itemsegmentCenter$ / shares | Jun. 30, 2021$ / shares | |
Segment Reporting Information [Line Items] | ||
Par value per share | $ / shares | $ 0.001 | $ 0.001 |
PACE | ||
Segment Reporting Information [Line Items] | ||
Number of reportable segments | segment | 1 | |
Number of PACE participants | item | 6,800 | |
Number of PACE centers excluding non-consolidating joint ventures | Center | 18 | |
Percentage of obligation for health care costs | 100.00% | |
Operating segments | PACE | ||
Segment Reporting Information [Line Items] | ||
Number of reportable segments | segment | 1 | |
Number of PACE participants | item | 6,800 |
Summary of Significant Accoun_4
Summary of Significant Accounting Policies - Effect of Restatement on Consolidated Balance Sheet (Details) - USD ($) $ in Thousands | Mar. 31, 2022 | Dec. 31, 2021 | Jun. 30, 2021 | Mar. 31, 2021 | Dec. 31, 2020 | Jun. 30, 2020 |
Error Corrections and Prior Period Adjustments Restatement [Line Items] | ||||||
Redeemable Noncontrolling Interests (See Note 4) | $ 15,996 | $ 18,850 | $ 16,986 | $ 16,919 | ||
Stockholders' Equity | ||||||
Retained earnings | 17,437 | 10,663 | ||||
Total InnovAge Holding Corp. | 343,919 | 334,559 | ||||
Noncontrolling interests | 6,207 | 6,420 | ||||
Total stockholders' equity | $ 350,126 | $ 349,586 | 340,979 | 334,142 | $ (31,289) | $ 107,750 |
As Previously Reported | ||||||
Stockholders' Equity | ||||||
Retained earnings | 11,250 | |||||
Total InnovAge Holding Corp. | 335,146 | |||||
Noncontrolling interests | 22,819 | |||||
Total stockholders' equity | 357,965 | 351,061 | ||||
Adjustments | ||||||
Error Corrections and Prior Period Adjustments Restatement [Line Items] | ||||||
Redeemable Noncontrolling Interests (See Note 4) | 16,986 | 16,919 | ||||
Stockholders' Equity | ||||||
Retained earnings | (587) | |||||
Total InnovAge Holding Corp. | (587) | |||||
Noncontrolling interests | (16,399) | |||||
Total stockholders' equity | $ (16,986) | $ (16,919) |
Summary of Significant Accoun_5
Summary of Significant Accounting Policies - Effect of Restatement on Consolidated Statements of Stockholders' Equity (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||||||
Mar. 31, 2022 | Mar. 31, 2021 | Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2021 | Jun. 30, 2021 | Dec. 31, 2020 | Jun. 30, 2020 | |
Error Corrections and Prior Period Adjustments Restatement [Line Items] | ||||||||
Net income (loss) | $ (2,868) | $ (10,599) | $ 5,975 | $ (50,792) | ||||
Adjustment to redemption value | 2,563 | (344) | 586 | (344) | ||||
Total Stockholders' Equity, Balances | 350,126 | 334,142 | 350,126 | 334,142 | $ 349,586 | $ 340,979 | $ (31,289) | $ 107,750 |
Temporary Equity, Accretion to Redemption Value, Adjustment | 16,838 | 16,838 | ||||||
Adjustment to redemption value | (2,563) | 344 | (586) | 344 | ||||
Net income (loss) | (290) | (263) | (403) | (263) | ||||
Redeemable Noncontrolling Interests | 15,996 | 16,919 | 15,996 | 16,919 | 18,850 | 16,986 | ||
Net Income (Loss) Attributable to Redeemable Noncontrolling Interest | (3,158) | (10,862) | 5,572 | (51,055) | ||||
Retained Earnings (Deficit) | ||||||||
Error Corrections and Prior Period Adjustments Restatement [Line Items] | ||||||||
Net income (loss) | (2,821) | (10,510) | 6,188 | (50,460) | ||||
Adjustment to redemption value | 2,563 | (344) | 586 | (344) | ||||
Total Stockholders' Equity, Balances | 17,437 | 4,476 | 17,437 | 4,476 | 17,695 | 10,663 | 15,330 | 64,737 |
Noncontrolling Interests | ||||||||
Error Corrections and Prior Period Adjustments Restatement [Line Items] | ||||||||
Net income (loss) | (47) | (89) | (213) | (332) | ||||
Total Stockholders' Equity, Balances | $ 6,207 | 6,403 | $ 6,207 | 6,403 | $ 6,254 | 6,420 | $ 6,492 | $ 6,735 |
As Previously Reported | ||||||||
Error Corrections and Prior Period Adjustments Restatement [Line Items] | ||||||||
Consolidation Of Equity Method Investment | 16,838 | 16,838 | ||||||
Net income (loss) | (10,862) | (51,055) | ||||||
Total Stockholders' Equity, Balances | 351,061 | 351,061 | 357,965 | |||||
As Previously Reported | Retained Earnings (Deficit) | ||||||||
Error Corrections and Prior Period Adjustments Restatement [Line Items] | ||||||||
Net income (loss) | (10,510) | (50,460) | ||||||
Total Stockholders' Equity, Balances | 4,820 | 4,820 | 11,250 | |||||
As Previously Reported | Noncontrolling Interests | ||||||||
Error Corrections and Prior Period Adjustments Restatement [Line Items] | ||||||||
Consolidation Of Equity Method Investment | 16,838 | 16,838 | ||||||
Net income (loss) | (352) | (595) | ||||||
Total Stockholders' Equity, Balances | 22,978 | 22,978 | 22,819 | |||||
Adjustments | ||||||||
Error Corrections and Prior Period Adjustments Restatement [Line Items] | ||||||||
Consolidation Of Equity Method Investment | (16,838) | (16,838) | ||||||
Net income (loss) | 263 | 263 | ||||||
Adjustment to redemption value | (344) | (344) | ||||||
Total Stockholders' Equity, Balances | (16,919) | (16,919) | (16,986) | |||||
Temporary Equity, Accretion to Redemption Value, Adjustment | 16,838 | 16,838 | ||||||
Adjustment to redemption value | 344 | 344 | ||||||
Net income (loss) | (263) | (263) | ||||||
Redeemable Noncontrolling Interests | 16,919 | 16,919 | 16,986 | |||||
Net Income (Loss) Attributable to Redeemable Noncontrolling Interest | (10,862) | (51,055) | ||||||
Adjustments | Retained Earnings (Deficit) | ||||||||
Error Corrections and Prior Period Adjustments Restatement [Line Items] | ||||||||
Adjustment to redemption value | (344) | (344) | ||||||
Total Stockholders' Equity, Balances | (344) | (344) | (587) | |||||
Adjustments | Noncontrolling Interests | ||||||||
Error Corrections and Prior Period Adjustments Restatement [Line Items] | ||||||||
Consolidation Of Equity Method Investment | (16,838) | (16,838) | ||||||
Net income (loss) | 263 | 263 | ||||||
Total Stockholders' Equity, Balances | $ (16,575) | $ (16,575) | $ (16,399) |
Summary of Significant Accoun_6
Summary of Significant Accounting Policies - Property and Equipment (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Mar. 31, 2022 | Mar. 31, 2021 | Mar. 31, 2022 | Mar. 31, 2021 | Jun. 30, 2021 | |
Summary of Significant Accounting Policies | |||||
Property and equipment gross | $ 217,739 | $ 217,739 | $ 187,491 | ||
Less accumulated depreciation and amortization | (53,857) | (53,857) | (44,776) | ||
Balance as of end of period | 163,882 | 163,882 | 142,715 | ||
Depreciation | 3,800 | $ 3,200 | 9,900 | $ 8,800 | |
Land | |||||
Summary of Significant Accounting Policies | |||||
Property and equipment gross | 11,980 | 11,980 | 11,980 | ||
Buildings and leasehold improvements | |||||
Summary of Significant Accounting Policies | |||||
Property and equipment gross | 121,661 | $ 121,661 | 104,724 | ||
Buildings and leasehold improvements | Minimum | |||||
Summary of Significant Accounting Policies | |||||
Estimated Useful Lives | 10 years | ||||
Buildings and leasehold improvements | Maximum | |||||
Summary of Significant Accounting Policies | |||||
Estimated Useful Lives | 40 years | ||||
Software | |||||
Summary of Significant Accounting Policies | |||||
Property and equipment gross | 15,107 | $ 15,107 | 13,316 | ||
Software | Minimum | |||||
Summary of Significant Accounting Policies | |||||
Estimated Useful Lives | 3 years | ||||
Software | Maximum | |||||
Summary of Significant Accounting Policies | |||||
Estimated Useful Lives | 5 years | ||||
Equipment and vehicles | |||||
Summary of Significant Accounting Policies | |||||
Property and equipment gross | 46,655 | $ 46,655 | 35,341 | ||
Equipment and vehicles | Minimum | |||||
Summary of Significant Accounting Policies | |||||
Estimated Useful Lives | 3 years | ||||
Equipment and vehicles | Maximum | |||||
Summary of Significant Accounting Policies | |||||
Estimated Useful Lives | 7 years | ||||
Construction in progress | |||||
Summary of Significant Accounting Policies | |||||
Property and equipment gross | $ 22,336 | $ 22,336 | $ 22,130 |
Summary of Significant Accoun_7
Summary of Significant Accounting Policies - COVID-19 (Details) - USD ($) $ in Millions | 9 Months Ended | 12 Months Ended | |
Mar. 31, 2022 | Jun. 30, 2021 | Jun. 30, 2020 | |
Summary of Significant Accounting Policies | |||
Funding received, COVID-19 | $ 1 | ||
Reimbursement amount allocated | $ 1 | ||
Reimbursement amount recognized | $ 0.3 | $ 0.7 |
Revenue Recognition (Details)
Revenue Recognition (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Mar. 31, 2022 | Mar. 31, 2021 | Mar. 31, 2022 | Mar. 31, 2021 | Jun. 30, 2021 | |
Revenue Recognition | |||||
Pooled capitated payment | 100.00% | ||||
Allowances for uncollectable accounts | $ 3,921 | $ 3,921 | $ 4,350 | ||
Capitated revenues | Customer concentration risk | |||||
Revenue Recognition | |||||
Risk percentage | 100.00% | 100.00% | |||
Medicare Part D | Capitated revenues | Customer concentration risk | |||||
Revenue Recognition | |||||
Risk percentage | 12.00% | 12.00% | |||
Medicare Part D | External provider costs. | Customer concentration risk | |||||
Revenue Recognition | |||||
Risk percentage | 23.00% | 25.00% | |||
Senior Housing | Other service revenue | Customer concentration risk | |||||
Revenue Recognition | |||||
Risk percentage | 0.20% | 0.30% | 0.20% | 0.40% |
Revenue Recognition - Source of
Revenue Recognition - Source of Revenue (Details) - Capitated revenues - Customer concentration risk | 9 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Disaggregation of Revenue [Line Items] | ||
Risk percentage | 100.00% | 100.00% |
Medicaid | ||
Disaggregation of Revenue [Line Items] | ||
Risk percentage | 53.00% | 53.00% |
Medicare | ||
Disaggregation of Revenue [Line Items] | ||
Risk percentage | 46.00% | 46.00% |
Private pay and other | ||
Disaggregation of Revenue [Line Items] | ||
Risk percentage | 1.00% | 1.00% |
Revenue Recognition - Concentra
Revenue Recognition - Concentration of Net Receivable (Details) - Accounts Receivable - Customer concentration risk | 9 Months Ended | 12 Months Ended |
Mar. 31, 2022 | Jun. 30, 2021 | |
Disaggregation of Revenue [Line Items] | ||
Risk percentage | 100.00% | 100.00% |
Medicaid | ||
Disaggregation of Revenue [Line Items] | ||
Risk percentage | 50.00% | 60.00% |
Medicare | ||
Disaggregation of Revenue [Line Items] | ||
Risk percentage | 37.00% | 20.00% |
Private pay and other | ||
Disaggregation of Revenue [Line Items] | ||
Risk percentage | 13.00% | 20.00% |
Investments - Equity Method and
Investments - Equity Method and Cost Method Investments (Details) - USD ($) $ in Thousands | Mar. 31, 2022 | Jun. 30, 2021 |
Investments | ||
Cost method investments | $ 4,645 | $ 2,645 |
Equity method investments | 848 | 848 |
Total investments | $ 5,493 | $ 3,493 |
Investments (Details)
Investments (Details) | Feb. 09, 2021USD ($) | Mar. 18, 2019USD ($)$ / shares | Aug. 31, 2021USD ($)shares | Mar. 31, 2022USD ($)item$ / shares | Mar. 31, 2021USD ($) | Dec. 31, 2020USD ($) | Mar. 31, 2022USD ($)item$ / shares | Mar. 31, 2021USD ($) | Jun. 30, 2021USD ($)$ / shares | Dec. 31, 2019USD ($) |
Investments | ||||||||||
Number of investments | item | 2 | 2 | ||||||||
Observable price changes | $ 0 | $ 0 | ||||||||
Cash consideration | 2,000,000 | |||||||||
Cost method investments | $ 4,645,000 | 4,645,000 | $ 2,645,000 | |||||||
Cash contributions | 20,000,000 | |||||||||
Cash | $ 9,000,000 | $ 199,493,000 | $ 199,493,000 | $ 201,466,000 | ||||||
Land | $ 4,200,000 | |||||||||
Par value per share | $ / shares | $ 0.001 | $ 0.001 | $ 0.001 | |||||||
Net loss, attributable to redeemable noncontrolling interest | $ (3,158,000) | $ (10,862,000) | $ 5,572,000 | $ (51,055,000) | ||||||
Change in fair value of warrants | $ 2,300,000 | |||||||||
Redeemable noncontrolling interests | 15,900,000 | 15,900,000 | ||||||||
Gain on consolidation | $ 10,900,000 | |||||||||
Adventist Health System/West Joint Venture | ||||||||||
Investments | ||||||||||
Percentage of issued and outstanding equity interests | 5.00% | |||||||||
Par value per share | $ / shares | $ 0.001 | |||||||||
Capital contributions | $ 25,000,000 | |||||||||
Warrants right to purchase common stock | $ 15,000,000 | |||||||||
Warrant exercise term | 1 year | |||||||||
InnovAge Sacramento | ||||||||||
Investments | ||||||||||
Membership interest (as a percent) | 59.90% | |||||||||
InnovAge Sacramento | ||||||||||
Investments | ||||||||||
Percentage of additional membership interest | 0.10% | 0.10% | 0.10% | |||||||
PWD | ||||||||||
Investments | ||||||||||
Maximum exposure amount in VIE | $ 800,000 | $ 800,000 | ||||||||
SH1 | ||||||||||
Investments | ||||||||||
Partnership interest (as a percent) | 0.01% | |||||||||
InnovAge California Pace-Sacramento, LLC | ||||||||||
Investments | ||||||||||
Cash contributions | $ 52,000 | |||||||||
InnovAge California Pace-Sacramento, LLC | Adventist Health System/West Joint Venture | ||||||||||
Investments | ||||||||||
Cash contributions | $ 5,800,000 | |||||||||
InnovAge California Pace-Sacramento, LLC | Eskaton | ||||||||||
Investments | ||||||||||
Cash contributions | $ 3,000,000 | |||||||||
InnovAge California Pace-Sacramento, LLC | InnovAge Sacramento | Adventist Health System/West Joint Venture | ||||||||||
Investments | ||||||||||
Membership interest (as a percent) | 26.40% | |||||||||
InnovAge California Pace-Sacramento, LLC | InnovAge Sacramento | Eskaton | ||||||||||
Investments | ||||||||||
Membership interest (as a percent) | 13.70% | |||||||||
Jetdoc, Inc. | ||||||||||
Investments | ||||||||||
Shares acquired | shares | 806,481 | |||||||||
Cash consideration | $ 2,000,000 | |||||||||
Maximum exposure to loss of the cost method investments | $ 2,000,000 | |||||||||
Dispatch Health Holdings, Inc. | ||||||||||
Investments | ||||||||||
Cost method investments | $ 2,600,000 | |||||||||
Maximum exposure to loss of the cost method investments | $ 2,600,000 | |||||||||
InnovAge Sacramento | ||||||||||
Investments | ||||||||||
Net loss, attributable to redeemable noncontrolling interest | $ (1,300,000) |
Fair Value Measurements (Detail
Fair Value Measurements (Details) - USD ($) | Mar. 08, 2021 | Aug. 07, 2018 | Mar. 31, 2022 | Mar. 31, 2022 | Mar. 31, 2021 | Jun. 30, 2021 |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | ||||||
Contingent consideration | $ 20,000,000 | $ 0 | $ 0 | $ 0 | ||
Contingent consideration paid | $ 20,000,000 | |||||
Transfers into Level 3 | $ 0 | $ 0 | ||||
InnovAge Sacramento | ||||||
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | ||||||
Changes in fair value | $ 2,600,000 | |||||
NewCourtland LIFE Program | ||||||
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | ||||||
Purchase price | 30,000,000 | |||||
NewCourtland LIFE Program | Maximum | ||||||
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | ||||||
Contingent consideration | $ 20,000,000 |
Goodwill and Intangible Asset_2
Goodwill and Intangible Assets (Details) $ in Thousands | 9 Months Ended | ||
Mar. 31, 2022USD ($)item | Mar. 31, 2021USD ($) | Jun. 30, 2021USD ($) | |
Goodwill and Intangible Assets | |||
Goodwill | $ 124,217 | $ 124,217 | |
Number of reporting units | item | 3 | ||
Impairment of goodwill | $ 0 | $ 0 | |
Amortization expense | 500 | 200 | |
Intangible asset impairments | $ 0 | $ 0 |
Goodwill and Intangible Asset_3
Goodwill and Intangible Assets - Intangible Asset by Major Class (Details) - USD ($) $ in Thousands | Mar. 31, 2022 | Jun. 30, 2021 |
Intangible Assets, Net (Including Goodwill) [Abstract] | ||
Definite-lived intangible assets | $ 9,350 | $ 6,600 |
Indefinite-lived intangible assets | 2,000 | 2,000 |
Total intangible assets | 11,350 | 8,600 |
Accumulated amortization | (2,578) | (2,082) |
Balance as of end of period | $ 8,772 | $ 6,518 |
Leases - Assets Under Lease (De
Leases - Assets Under Lease (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Mar. 31, 2022 | Mar. 31, 2021 | Mar. 31, 2022 | Mar. 31, 2021 | Jun. 30, 2021 | |
Operating Leased Assets [Line Items] | |||||
Equipment | $ 217,739 | $ 217,739 | $ 187,491 | ||
Less accumulated depreciation | (53,857) | (53,857) | (44,776) | ||
Balance as of end of period | 163,882 | 163,882 | 142,715 | ||
Rental expense | 1,300 | $ 1,400 | 3,500 | $ 3,500 | |
Equipment under capital leases | |||||
Operating Leased Assets [Line Items] | |||||
Equipment | 18,885 | 18,885 | 13,302 | ||
Less accumulated depreciation | (7,150) | (7,150) | (7,081) | ||
Balance as of end of period | $ 11,735 | $ 11,735 | $ 6,221 |
Leases - Future Minimum Lease P
Leases - Future Minimum Lease Payments (Details) $ in Thousands | Mar. 31, 2022USD ($) |
Capital Leases Obligations | |
Amount Remaining in 2022 | $ 958 |
2023 | 4,405 |
2024 | 3,909 |
2025 | 3,126 |
2026 | 2,092 |
Thereafter | 1,927 |
Total | 16,417 |
Less amount representing interest | (2,912) |
Total minimum lease payments | 13,498 |
Less current maturities | (3,216) |
Noncurrent maturities | 10,282 |
Operating Leases Minimum Lease Payments | |
Amount Remaining in 2022 | 1,203 |
2023 | 4,872 |
2024 | 4,582 |
2025 | 4,122 |
2026 | 4,061 |
Thereafter | 14,029 |
Total | $ 32,869 |
Long Term Debt - Schedule of Lo
Long Term Debt - Schedule of Long-term Debt (Details) - USD ($) $ in Thousands | Mar. 31, 2022 | Jun. 30, 2021 |
Debt Instrument [Line Items] | ||
Total debt | $ 74,526 | $ 77,367 |
Less unamortized debt issuance costs | 1,681 | 2,003 |
Less current maturities | 3,793 | 3,790 |
Noncurrent maturities | 69,051 | 71,574 |
Senior secured term loan | ||
Debt Instrument [Line Items] | ||
Total debt | 72,188 | 75,000 |
Convertible term loan | ||
Debt Instrument [Line Items] | ||
Total debt | $ 2,338 | $ 2,367 |
Interest rate (as a percent) | 6.68% | 6.68% |
Long Term Debt (Details)
Long Term Debt (Details) - USD ($) | Mar. 08, 2021 | Jul. 27, 2020 | Sep. 01, 2015 | Mar. 31, 2022 | Mar. 31, 2021 | Jun. 30, 2021 | May 02, 2019 | May 13, 2016 |
Debt Instrument [Line Items] | ||||||||
Loss on extinguishment of long-term debt | $ 8,494,000 | |||||||
Outstanding borrowings | $ 74,526,000 | $ 77,367,000 | ||||||
Revolving credit facility | ||||||||
Debt Instrument [Line Items] | ||||||||
Remaining borrowing capacity | 100,000,000 | |||||||
Letters of credit, issued amounts | 2,600,000 | |||||||
Senior secured term loan | ||||||||
Debt Instrument [Line Items] | ||||||||
Outstanding borrowings | 72,188,000 | 75,000,000 | ||||||
Convertible term loan | ||||||||
Debt Instrument [Line Items] | ||||||||
Outstanding borrowings | $ 2,338,000 | $ 2,367,000 | ||||||
Interest rate (as a percent) | 6.68% | 6.68% | ||||||
Monthly principal and interest payments | $ 20,000 | |||||||
2016 Credit Agreement | ||||||||
Debt Instrument [Line Items] | ||||||||
Debt extinguishment | 57,100,000 | |||||||
Loss on extinguishment of long-term debt | 1,000,000 | |||||||
Modified debt | $ 250,000,000 | |||||||
Outstanding borrowings | 50,000,000 | |||||||
Amortization of deferred financing costs | $ 900,000 | |||||||
Total deferred financing costs | 9,100,000 | |||||||
2016 Credit Agreement | Revolving credit facility | ||||||||
Debt Instrument [Line Items] | ||||||||
Loan amount | $ 40,000,000 | $ 30,000,000 | $ 20,000,000 | |||||
2016 Credit Agreement | Senior secured term loan | ||||||||
Debt Instrument [Line Items] | ||||||||
Loan amount | 300,000,000 | 190,000,000 | $ 75,000,000 | |||||
2016 Credit Agreement | Delayed draw term loan facility (DDTL) | ||||||||
Debt Instrument [Line Items] | ||||||||
Loan amount | $ 45,000,000 | |||||||
Termination of loan | $ 45,000,000 | |||||||
2021 Credit Agreement | Revolving credit facility | ||||||||
Debt Instrument [Line Items] | ||||||||
Loan amount | $ 100,000,000 | |||||||
Outstanding borrowings | 0 | |||||||
Amortization of deferred financing costs | 300,000 | |||||||
Total deferred financing costs | $ 2,000,000 | |||||||
Revolving credit facility fee | 0.25% | |||||||
2021 Credit Agreement | Senior secured term loan | ||||||||
Debt Instrument [Line Items] | ||||||||
Loan amount | $ 75,000,000 | |||||||
Percentage of aggregate outstanding principal amount | 1.25% | |||||||
Interest rate (as a percent) | 2.21% |
Equity (Details)
Equity (Details) - USD ($) $ in Thousands | Jul. 27, 2020 | Mar. 31, 2021 | Mar. 31, 2022 | Jun. 30, 2021 |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Reduction in additional paid-in capital | $ 326,346 | $ 323,760 | ||
Transaction costs | $ 22,600 | |||
Dividends | 9,500 | |||
General and administrative expense | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Transaction costs | $ 13,100 | |||
Credit Agreement | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Repurchase (in shares) | 16,095,819 | |||
Repurchase | $ 77,600 | |||
Cancellation Agreement | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Corporate, general and administrative expense | 45,400 | |||
Reduction in additional paid-in capital | $ 32,400 | |||
2016 Incentive Plan | Cancellation Agreement | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Shares cancelled (in shares) | 16,994,975 | |||
Shares cancelled | $ 74,600 |
Stock-based Compensation - Comp
Stock-based Compensation - Compensation Expense (Details) - USD ($) $ in Thousands | 9 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Total share-based compensation expense | $ 2,586 | $ 46,489 |
Stock Options | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Total share-based compensation expense | 359 | 45,387 |
Profits Interests Units | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Total share-based compensation expense | 1,095 | $ 1,102 |
Restricted Stock Units | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Total share-based compensation expense | $ 1,132 |
Stock-based Compensation - Equi
Stock-based Compensation - Equity Incentive Plan (Details) - 2016 Equity Incentive Plan - shares | Jul. 27, 2020 | Mar. 31, 2022 |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Number of shares authorized | 17,836,636 | |
Granted (in shares) | 16,994,976 | |
Repurchase (in shares) | 16,095,819 | |
Number of shares cancelled | 16,994,976 |
Stock-based Compensation - Prof
Stock-based Compensation - Profits Interests (Details) - 2020 Equity Incentive Plan | 9 Months Ended |
Mar. 31, 2022shares | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Number of shares authorized | 16,162,177 |
Profits interests granted | 13,009,137 |
Granted (in shares) | 0 |
Stock-based Compensation - Pr_2
Stock-based Compensation - Profits Interests Transactions and Number of Units Outstanding (Details) | 9 Months Ended |
Mar. 31, 2022$ / sharesshares | |
Time Vesting Units | |
Number of Units | |
Outstanding balance, June 30, 2021 | shares | 6,587,261 |
Forfeited | shares | (2,409,972) |
Outstanding balance, March 31, 2022 | shares | 4,177,289 |
Weighted-Average Grant Date FV | |
Outstanding balance, June 30, 2021 | $ / shares | $ 1.28 |
Forfeited | $ / shares | 1.28 |
Outstanding balance, March 31, 2022 | $ / shares | $ 1.28 |
Performance Vesting Units | |
Number of Units | |
Outstanding balance, June 30, 2021 | shares | 6,223,262 |
Forfeited | shares | (3,210,939) |
Outstanding balance, March 31, 2022 | shares | 3,012,323 |
Weighted-Average Grant Date FV | |
Outstanding balance, June 30, 2021 | $ / shares | $ 0.57 |
Forfeited | $ / shares | 0.57 |
Outstanding balance, March 31, 2022 | $ / shares | $ 0.57 |
Stock-based Compensation - Mont
Stock-based Compensation - Monte Carlo Option Pricing Model (Details) $ / shares in Units, $ in Millions | 9 Months Ended |
Mar. 31, 2022USD ($)$ / shares | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Expected term (in years) | 2 years 10 months 24 days |
Profits Interests Units | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Unrecognized compensation cost | $ | $ 6.4 |
Time Vesting Units | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Unrecognized compensation cost | $ | $ 4.3 |
Weighted-average period (in years) | 10 months 24 days |
Performance Vesting Units | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Unrecognized compensation cost | $ | $ 2.1 |
Time-based option awards | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Expected volatility | 34.50% |
Interest rate | 0.83% |
Dividend yield | 0.00% |
Weighted-average fair values | $ / shares | $ 1.61 |
Fair value of underlying stock | $ / shares | $ 7.89 |
Weighted-average period (in years) | 2 years 6 months |
Performance-based option awards | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Weighted-average period (in years) | 3 years 7 months 6 days |
Performance Based Restricted Stock Units [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Expected volatility | 34.50% |
Expected term (in years) | 5 years |
Interest rate | 1.56% |
Dividend yield | 0.00% |
Weighted-average fair values | $ / shares | $ 5.18 |
Fair value of underlying stock | $ / shares | $ 7.89 |
Unrecognized compensation cost | $ | $ 1.2 |
Weighted-average period (in years) | 3 years 7 months 6 days |
Minimum | Time-based option awards | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Expected term (in years) | 2 years 10 months 24 days |
Stock-based Compensation - 2021
Stock-based Compensation - 2021 Omnibus Incentive Plan (Details) $ in Millions | 9 Months Ended |
Mar. 31, 2022USD ($)shares | |
2021 Omnibus Incentive Plan | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Number of shares authorized | shares | 14,700,000 |
Vesting period | 3 years |
Percentage of vesting | 33.33% |
Performance Based Restricted Stock Units [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Unrecognized compensation cost | $ 1.2 |
Weighted-average period (in years) | 3 years 7 months 6 days |
Time Based Restricted Stock Units [Member] | 2021 Omnibus Incentive Plan | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Unrecognized compensation cost | $ 4 |
Weighted-average period (in years) | 2 years |
Performance-based option awards | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |
Weighted-average period (in years) | 3 years 7 months 6 days |
Stock-based Compensation - 20_2
Stock-based Compensation - 2021 Omnibus Incentive Plan (RSU Activity) (Details) - 2021 Omnibus Incentive Plan | 9 Months Ended |
Mar. 31, 2022$ / sharesshares | |
Time Based Restricted Stock Units [Member] | |
Number of Units | |
Outstanding balance, June 30, 2021 | shares | 48,470 |
Granted | shares | 315,177 |
Forfeited | shares | (9,670) |
Exercised | shares | (8,493) |
Outstanding balance, March 31, 2022 | shares | 345,484 |
Weighted-Average Grant Date FV | |
Outstanding balance, June 30, 2021 | $ / shares | $ 22.87 |
Granted | $ / shares | 8.99 |
Forfeited | $ / shares | 23.35 |
Exercised | $ / shares | 17.66 |
Outstanding balance, March 31, 2022 | $ / shares | $ 10.50 |
Performance Based Restricted Stock Units [Member] | |
Number of Units | |
Granted | shares | 258,767 |
Outstanding balance, March 31, 2022 | shares | 258,767 |
Weighted-Average Grant Date FV | |
Granted | $ / shares | $ 5.18 |
Outstanding balance, March 31, 2022 | $ / shares | $ 5.18 |
Stock-based Compensation - Time
Stock-based Compensation - Time-based Awards (Details) - Time-based option awards $ / shares in Units, $ in Millions | 9 Months Ended |
Mar. 31, 2022USD ($)$ / sharesshares | |
Number of Options | |
Granted (in shares) | shares | 554,499 |
Outstanding balance, March 31, 2022 | shares | 554,499 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] | |
Granted | $ / shares | $ 1.61 |
Outstanding balance, March 31, 2022 | $ / shares | $ 1.61 |
Unrecognized compensation cost | $ | $ 0.7 |
Weighted-average period (in years) | 2 years 6 months |
Stock-based Compensation - Perf
Stock-based Compensation - Performance-based Awards (Details) - Performance-based option awards $ / shares in Units, $ in Millions | 9 Months Ended |
Mar. 31, 2022USD ($)$ / sharesshares | |
Number of Options | |
Granted (in shares) | shares | 776,299 |
Outstanding balance, March 31, 2022 | shares | 776,299 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] | |
Outstanding balance, June 30, 2021 | $ 3.08 |
Granted | 3.08 |
Outstanding balance, March 31, 2022 | $ 3.08 |
Unrecognized compensation cost | $ | $ 2.2 |
Weighted-average period (in years) | 3 years 7 months 6 days |
Income Taxes (Details)
Income Taxes (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Mar. 31, 2022 | Mar. 31, 2021 | Mar. 31, 2022 | Mar. 31, 2021 | |
Income Taxes | ||||
Effective tax rate (as a percent) | 1.40% | (11.20%) | ||
Income tax provision | $ (4,116) | $ (4,264) | $ 81 | $ 5,159 |
Federal statutory tax rate (as a percent) | 56.60% | |||
Federal statutory tax rate (as a percent) | 28.20% |
Earnings per Share (Details)
Earnings per Share (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Mar. 31, 2022 | Mar. 31, 2021 | Mar. 31, 2022 | Mar. 31, 2021 | |
Earnings per Share | ||||
Net income (loss) attributable to InnovAge Holding Corp. | $ (2,821) | $ (10,510) | $ 6,188 | $ (50,460) |
Weighted average common shares outstanding (basic) | 135,516,608 | 121,324,980 | 135,516,544 | 119,619,806 |
Earnings (loss) per share - basic | $ (0.02) | $ (0.09) | $ 0.05 | $ (0.42) |
Dilutive shares | 14,249 | |||
Weighted average common shares outstanding (diluted) | 135,516,608 | 121,324,980 | 135,530,793 | 119,619,806 |
Earnings (loss) per share -diluted | $ (0.02) | $ (0.09) | $ 0.05 | $ (0.42) |
Segment Reporting (Details)
Segment Reporting (Details) | 9 Months Ended |
Mar. 31, 2022divisionitemsegmentCenter | |
PACE | |
Segment Reporting Information [Line Items] | |
Number of operating segments | 3 |
Number of reportable segments | 1 |
Number of PACE participants | item | 6,800 |
Operating segments | |
Segment Reporting Information [Line Items] | |
Number of operating segments | 5 |
Operating segments | PACE | |
Segment Reporting Information [Line Items] | |
Number of geographic divisions | division | 3 |
Number of reportable segments | 1 |
Number of PACE participants | item | 6,800 |
Number of PACE centers | Center | 18 |
Operating segments | Others | |
Segment Reporting Information [Line Items] | |
Number of operating segments | 2 |
Segment Reporting - Operating R
Segment Reporting - Operating Results (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Mar. 31, 2022 | Mar. 31, 2021 | Mar. 31, 2022 | Mar. 31, 2021 | |
Segment Reporting Information [Line Items] | ||||
Total revenues | $ 177,359 | $ 156,308 | $ 525,780 | $ 466,184 |
External provider costs | 103,254 | 75,389 | 284,299 | 224,215 |
Cost of care, excluding depreciation and amortization | 46,102 | 39,565 | 129,740 | 115,922 |
Equity loss | (1,343) | |||
Other operating (income) expense | (19,222) | (18,211) | ||
Interest expense, net | (709) | (4,876) | (1,930) | (17,061) |
Loss on extinguishment of debt | (8,494) | |||
Gain on equity method investment | (10,871) | (10,871) | ||
Other income | 108 | (2,267) | (358) | (2,222) |
Income (Loss) Before Income Taxes | (7,274) | (15,126) | 5,653 | (45,896) |
Capitation revenue | ||||
Segment Reporting Information [Line Items] | ||||
Total revenues | 176,988 | 155,835 | 524,507 | 464,294 |
Other service revenue | ||||
Segment Reporting Information [Line Items] | ||||
Total revenues | 371 | 473 | 1,273 | 1,890 |
Operating segments | ||||
Segment Reporting Information [Line Items] | ||||
Total revenues | 177,359 | 156,308 | 525,780 | 466,184 |
External provider costs | 103,254 | 75,389 | 284,299 | 224,215 |
Cost of care, excluding depreciation and amortization | 46,102 | 39,565 | 129,740 | 115,922 |
Center-Level Contribution Margin | 28,003 | 41,354 | 111,741 | 126,047 |
Overhead costs | 30,826 | 24,187 | 93,365 | 120,236 |
Depreciation and amortization | 3,850 | 3,311 | 10,435 | 9,262 |
Equity loss | 1,343 | |||
Other operating (income) expense | 19,222 | 18,211 | ||
Interest expense, net | (709) | (4,876) | (1,930) | (17,061) |
Loss on extinguishment of debt | (13,488) | (14,479) | ||
Gain on equity method investment | 10,871 | 10,871 | ||
Other income | 108 | (2,267) | (358) | (2,222) |
Income (Loss) Before Income Taxes | (7,274) | (15,126) | 5,653 | (45,896) |
Operating segments | Capitation revenue | ||||
Segment Reporting Information [Line Items] | ||||
Total revenues | 176,988 | 155,835 | 524,507 | 464,294 |
Operating segments | Other service revenue | ||||
Segment Reporting Information [Line Items] | ||||
Total revenues | 371 | 473 | 1,273 | 1,890 |
Operating segments | PACE | ||||
Segment Reporting Information [Line Items] | ||||
Total revenues | 177,154 | 155,788 | 524,741 | 464,507 |
External provider costs | 103,254 | 75,389 | 284,299 | 224,215 |
Cost of care, excluding depreciation and amortization | 45,995 | 38,867 | 128,573 | 113,611 |
Center-Level Contribution Margin | 27,905 | 41,532 | 111,869 | 126,681 |
Overhead costs | 30,911 | 24,217 | 93,463 | 120,249 |
Depreciation and amortization | 3,760 | 3,181 | 10,130 | 8,901 |
Equity loss | 1,343 | |||
Other operating (income) expense | 19,222 | 18,211 | ||
Interest expense, net | (663) | (4,824) | (1,783) | (16,919) |
Loss on extinguishment of debt | (13,488) | (14,479) | ||
Gain on equity method investment | 10,871 | 10,871 | ||
Other income | 108 | (2,267) | (357) | (2,222) |
Income (Loss) Before Income Taxes | (7,321) | (14,796) | 6,136 | (44,772) |
Operating segments | PACE | Capitation revenue | ||||
Segment Reporting Information [Line Items] | ||||
Total revenues | 176,988 | 155,835 | 524,507 | 464,294 |
Operating segments | PACE | Other service revenue | ||||
Segment Reporting Information [Line Items] | ||||
Total revenues | 166 | (47) | 234 | 213 |
Operating segments | Others | ||||
Segment Reporting Information [Line Items] | ||||
Total revenues | 205 | 520 | 1,039 | 1,677 |
Cost of care, excluding depreciation and amortization | 107 | 698 | 1,167 | 2,311 |
Center-Level Contribution Margin | 98 | (178) | (128) | (634) |
Overhead costs | (85) | (30) | (98) | (13) |
Depreciation and amortization | 90 | 130 | 305 | 361 |
Interest expense, net | (46) | (52) | (147) | (142) |
Other income | (1) | |||
Income (Loss) Before Income Taxes | 47 | (330) | (483) | (1,124) |
Operating segments | Others | Other service revenue | ||||
Segment Reporting Information [Line Items] | ||||
Total revenues | $ 205 | $ 520 | $ 1,039 | $ 1,677 |
Related-party (Details)
Related-party (Details) - USD ($) | 9 Months Ended | |
Mar. 31, 2022 | Jun. 30, 2021 | |
Related Party Transaction [Line Items] | ||
Revenue from related parties | $ 35,000 | |
Deposits and other | ||
Related Party Transaction [Line Items] | ||
Loans and leases receivable, related parties | $ 700,000 | $ 700,000 |